D.C. Code § 48-803.03a — DC Code / Title 48 / Chapter 8 / § 48-803.03a
§ 48-803.03a. Dispensing of substitute drug products by pharmacists — notification of substitution.
Status: in_force

(a) An individual shall be notified of a drug substitution, including an interchangeable biological product, and provided the right to refuse the substitution prior to purchase of the substitute drug product.
(b) (1) The Department of Health shall create and distribute to all pharmacies signs that state in block letters not less than one inch in height: “This pharmacy may substitute a less expensive drug product that is equivalent to the one prescribed by your health care practitioner unless you request otherwise.
  (2) Each pharmacy shall display the sign in a prominent place that has a clear and unobstructed public view at or near the place where prescriptions are dispensed.
D.C. Code § 48-853.07 — DC Code / Title 48 / Chapter 8G / § 48-853.07
§ 48-853.07. Criteria for indicators of misuse; Director’s authority to disclose information; intervention.
Status: in_force

(a) The Director may establish through rulemaking:
  (1) Criteria for indicators of misuse or abuse of covered substances;
  (2) A method for analysis of data collected by the Program using the criteria for indicators of misuse or abuse of covered substances;
  (3) Criteria for indications of a possible violation of law or a possible breach of professional standards by a prescriber or dispenser; and
  (4) A method for analysis of data collected by the Program using the criteria for indications of a possible violation of law or a possible breach of professional standards by a prescriber or dispenser.
(b) (1) Upon the development of the criteria and data analysis, the Program may review prescription monitoring program data for indications of:
    (A) Possible misuse or abuse of a covered prescription drug; and
    (B) A possible violation of law or possible breach of professional standards by a prescriber or a dispenser.
  (2) If the Program's review of prescription monitoring data indicates a possible violation of paragraph (1) of this subsection, the Director may, in addition to any discretionary disclosure of information pursuant to this chapter :
    (A) Report the possible misuse or abuse by a patient to the specific prescriber or dispenser of the covered prescription drug for the purpose of intervention to prevent such misuse or abuse;
    (B) Notify the prescriber or dispenser of the possible violation of law or possible breach of professional standards; and
    (C) Provide education to the prescriber or dispenser.
D.C. Code § 48-843.03 — DC Code / Title 48 / Chapter 8D / § 48-843.03
§ 48-843.03. Establishment of the Pharmaceutical Education Program.
Status: in_force

(a) There is established an evidence-based Pharmaceutical Education Program (“Program”) within the Department of Health. The Program shall:
  (1) Educate prescribers who participate in the District of Columbia Medicaid program, and other publicly funded, contracted, or subsidized health-care programs, on the therapeutic and cost-effective utilization of pharmaceutical products;
  (2) Inform prescribers about pharmaceutical product marketing practices that are intended to circumvent competition from generic, other therapeutically-equivalent alternatives, or other evidence-based treatment options; and
  (3) Utilize, or incorporate into the Program, other independent educational resources or models proven effective in promoting high-quality, evidenced-based, cost-effective information regarding the effectiveness and safety of pharmaceutical products.
(b) The Program shall be made available to prescribers who do not participate in the District of Columbia Medicaid program or other publicly funded, contracted, or subsidized health-care programs on a subscription basis.
(c) If approved by the Board of Medicine, the PE program may be used to satisfy continuing education requirements for the practice of medicine.
D.C. Code § 48-904.03 — DC Code / Title 48 / Chapter 9 / § 48-904.03
§ 48-904.03. Prohibited acts C; penalties.
Status: in_force

(a) It is unlawful for any person knowingly or intentionally:
  (1) To distribute as a registrant a controlled substance classified in Schedule I or II, except pursuant to an order form as required by § 48-903.07 ;
  (2) To use in the course of the manufacture or distribution of a controlled substance a registration number which is fictitious, revoked, suspended, or issued to another person;
  (3) To acquire or obtain possession of a controlled substance by misrepresentation, fraud, forgery, deception, or subterfuge;
  (4) To furnish false or fraudulent material information in, or omit any material information from, any application, report, or other document required to be kept or filed under this chapter, or any record required to be kept by this chapter; or
  (5) To make, distribute, or possess any punch, die, plate, stone, or other thing designed to print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or device of another or any likeness of any of the foregoing upon any drug or container or labeling thereof so as to render the drug a counterfeit substance.
(b) Any person who violates this section is guilty of a crime and upon conviction may be imprisoned for not more than 4 years, fined not more than the amount set forth in § 22-3571.01 , or both.
D.C. Code § 48-314 — DC Code / Title 48 / Chapter 3A / § 48-314
§ 48-314. Appointment and duties of Food Policy Director.
Status: in_force

(a) The Mayor shall appoint a Food Policy Director ("Director") within the Office of Planning with the advice and consent of the Council of the District of Columbia to promote equitable and sustainable food policies across the District that increase food access and build a local food economy.
(b) The Director shall:
  (1) Collaborate with other jurisdictions to promote locally-grown and sustainable food production practices;
  (2) Seek outside grants, recognition, and partnerships to facilitate positive food policy in the District;
  (3) Provide assistance to participants in the local food economy in securing necessary permits and approvals and in navigating the regulatory process;
  (4) Advocate for new local food economy ventures to locate in the District;
  (5) Devise strategies for the District to meet the food goals identified in the Sustainable DC Plan issued by the Mayor in 2013; and
  (6) Work with relevant agencies to reduce regulatory burdens on the local food economy.
D.C. Code § 48-902.10 — DC Code / Title 48 / Chapter 9 / § 48-902.10
§ 48-902.10. Schedule IV enumerated.
Status: in_force

(a) The controlled substances listed in this section are included in Schedule IV, unless and until removed therefrom pursuant to § 48-902.01 :
  (1) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
    (A) Barbital;
    (B) Chloral betaine;
    (C) Chloral hydrate;
    (D) Chlordiazepoxide;
    (E) Clonazepam;
    (F) Clorazepate;
    (G) Dextropropoxyphene;
    (H) Diazepam;
    (I) Ethchlorvynol;
    (J) Ethinamate;
    (K) Flurazepam;
    (L) Lorazepam;
    (M) Mebutamate;
    (N) Meprobamate;
    (O) Methohexital;
    (P) Methylphenobarbital (mephobarbital);
    (Q) Oxazepam;
    (R) Paraldehyde;
    (S) Petrichloral;
    (T) Phenobarbital;
    (U) Prazepam;
    (V) Alprazolam;
    (W) Bromazepam;
    (X) Camazepam;
    (Y) Clobazam;
    (Z) Clotiazepam;
    (AA) Cloxazolam;
    (BB) Delorazepam;
    (CC) Estazolam;
    (DD) Ethyl loflazepate;
    (EE) Fludiazepam;
    (FF) Flunitrazepam;
    (GG) Halazepam;
    (HH) Haloxazolam;
    (II) Ketazolam;
    (JJ) Loprazolam;
    (KK) Lormetazepam;
    (LL) Medazepam;
    (MM) Midazolam;
    (NN) Nimetazepam;
    (OO) Nitrazepam;
    (PP) Oxazolam;
    (QQ) Omitted;
    (RR) Pinazepam;
    (SS) Quazepam;
    (TT) Temazepam;
    (UU) Tetrazepam;
    (VV) Triazolam; and
    (WW) Fospropofol;
  (2) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible, such as Fenfluramine;
  (3) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
    (A) Diethylpropion;
    (B) Phentermine;
    (C) Pemoline (including organometallic complexes and chelates thereof);
    (D) Cathine;
    (E) Fencamfimin;
    (F) Fenproporex;
    (G) Mefenorex;
    (H) Pipradrol; and
    (I) SPA;
  (4) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:
    (A) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1), 2-diphenyl-1-3-methyl-2-propionoxybutane; and
    (B) Pentazocine; and
  (5) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof of not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
(b) The Mayor may except by rule any compound, mixture, or preparation containing any depressant substance listed in paragraph (1) of subsection (a) of this section from the application of all or any part of this chapter if the compound, mixture, or preparation contains 1 or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.
D.C. Code § 48-905.02 — DC Code / Title 48 / Chapter 9 / § 48-905.02
§ 48-905.02. Forfeitures.
Status: in_force

(a) The following property is subject to forfeiture if determined to be used in furtherance of or as proceeds of the manufacture or distribution of a controlled substance as prohibited by §  48-904.01(a) : containers, conveyances, equipment, raw materials, real property, money, currency, securities, negotiable instruments, instrumentalities, books, records, and research products, including formulas and data.
(b) Contraband is not subject to forfeiture under this section, but may be seized and disposed of in accordance with applicable law; provided, that controlled substances shall be retained until the prosecutorial authority responsible for prosecuting a violation under this chapter certifies that such controlled substances are no longer needed as evidence.
(c) No property shall be subject to forfeiture for conduct involving only a violation of § 48-904.01(d) .
(d) All seizures and forfeitures under this section shall follow the standards and procedures set forth in D.C. Law 20-278 .
D.C. Code § 48-804.02 — DC Code / Title 48 / Chapter 8 / § 48-804.02
§ 48-804.02. Restraints of trade.
Status: in_force

Any person who, by any means, interferes with, prevents, discourages, or attempts to interfere with, prevent, or discourage: (1) any disclosure of, or attempt to disclose, or action necessary to disclose, substantially accurate prices, discounts, services, or other information concerning any prescription drug, whether or not such disclosure is authorized or directed in this chapter, or is through any media or other form of communication, or is made or to be made by any publisher, broadcaster, pharmacy, pharmacist, advertiser, drug manufacturer, wholesaler, or chain, government agency, or any other person; or (2) any retail drug price-setting, substitution, or marketing policy or action required, encouraged or permitted by, or consistent with this chapter; has committed a restraint of trade, and has caused a tortious injury in the District of Columbia as described in § 13-423(a)(3) and (4), and shall be liable for treble civil damages to each and every person (including a pharmacy or pharmacist), health insurer, and government agency the object of or injured by such interference, prevention, discouragement, or attempt to interfere, prevent, or discourage. Any action which jeopardizes in any way, or raises the net price of, the supply from manufacturers or wholesalers of drugs to any pharmacy, government agency, health insurer, or person providing or paying for a drug in the District may comprise such an interference, prevention, discouragement, or attempt.
D.C. Code § 48-1005 — DC Code / Title 48 / Chapter 10 / § 48-1005
§ 48-1005. Penalties.
Status: in_force

(a) Any person who violates § 48-1004 shall, upon conviction, be subject to a fine of not more than $300, imprisonment for not more than 180 days, or both.
(b) The fine set forth in this section shall not be limited by § 22-3571.01 .
D.C. Code § 48-904.03a — DC Code / Title 48 / Chapter 9 / § 48-904.03a
§ 48-904.03a. Prohibited acts D; penalties.
Status: in_force

(a) It shall be unlawful for any person to knowingly open or maintain any place to manufacture, distribute, or store for the purpose of manufacture or distribution a narcotic or abusive drug.
(b) Any person who violates this section shall be imprisoned for not less than 5 years nor more than 25 years, fined not more than the amount set forth in § 22-3571.01 , or both.
D.C. Code § 48-314.01 — DC Code / Title 48 / Chapter 3A / § 48-314.01
§ 48-314.01. Grant-making authority.
Status: in_force

The Director of the Office of Planning shall have grant-making authority for the purpose of food policy development and implementation.
D.C. Code § 48-831.08 — DC Code / Title 48 / Chapter 8A / § 48-831.08
§ 48-831.08. Discrepancies in rebate amounts.
Status: in_force

(a) (1) Upon receipt of the data from the Department, the manufacturer or labeler shall calculate the quarterly payment. If a discrepancy is discovered, the Department may, at its expense, hire a mutually agreed-upon independent auditor to verify the manufacturer’s calculation. If a discrepancy is still found, the manufacturer or labeler shall justify its calculation or make payments to the Department for any additional amount due. The manufacturer or labeler may, at its expense, hire a mutually agreed-upon independent auditor to verify the accuracy of the utilization data provided by the Department. If a discrepancy is discovered, the Department shall justify its data or refund any excess payment to the manufacturer or labeler.
  (2) If the dispute over the rebate amount is not resolved, a request for a hearing with supporting documentation shall be submitted to the Office of Administrative Hearings. Failure to resolve the dispute may be cause for terminating the drug rebate agreement and denying payment to the manufacturer or labeler for any drugs.
(b) All prescription drugs of a manufacturer or labeler that enters into a rebate agreement that appear on the list of approved drugs shall be immediately available and the cost of the drugs shall be reimbursed, except as provided in this section.
D.C. Code § 48-653 — DC Code / Title 48 / Chapter 6A / § 48-653
§ 48-653. Customer disclosure requirement.
Status: in_force

(a) In addition to the price of items being selected for purchase and delivery from a restaurant through a third-party meal delivery platform, the third-party meal delivery platform shall disclose to the customer, regardless of where the restaurant is located, in plain language and in a conspicuous manner, any commission, fee, or other monetary payment to be charged to the customer by the third-party meal delivery platform ("charges"):
  (1) The subtotal of charges on the product page along with the price of the item as each item is selected; and
  (2) The total of charges and prices before the transaction is completed and the customer is charged.
D.C. Code § 48-831.07 — DC Code / Title 48 / Chapter 8A / § 48-831.07
§ 48-831.07. Operation of program.
Status: in_force

(a) Participating retail pharmacies shall submit claims to the Department to verify the amount charged to qualified residents and to receive reimbursement.
(b) The Department shall not impose transaction charges on participating retail pharmacies that submit claims or receive payments under AccessRx.
(c) On a periodic basis, to be established by the Department, the Department shall reimburse a participating retail pharmacy for:
  (1) The discounted price provided to uninsured qualified residents pursuant to § 48-831.33 ; and
  (2) Prescription drugs dispensed to low-income elderly pursuant to § 48-831.23 .
(d) The Department shall conduct ongoing quality assurance activities similar to those used in the D.C. Medicaid program.
(e) The Department shall collect utilization data from participating retail pharmacies submitting claims necessary to calculate the amount of the rebate from the manufacturer or labeler. The Department shall protect the confidentiality of all information subject to confidentiality protection under District or federal law, rule or regulation.
D.C. Code § 48-714 — DC Code / Title 48 / Chapter 7 / § 48-714
§ 48-714. Rules.
Status: in_force

(a) The Mayor shall issue rules pursuant to this chapter in accordance with the provisions of subchapter I of Chapter 5 of Title 2 .
(b) The proposed rules shall include, but not be limited to:
  (1) A schedule of license fees;
  (2) Standards for the exemption of certain employees employed by a licensed manufacturer, distributor, or wholesaler;
  (3) Procedures to govern the issuance, denial, renewal, suspension, conversion, or revocation of a license; and
  (4) Standards pertaining to labeling, handling, recordkeeping, and storage.
D.C. Code § 48-855.02b — DC Code / Title 48 / Chapter 8H / § 48-855.02b
§ 48-855.02b. Calculation of member's contributions for a prescription drug covered under the health benefit plan.
Status: in_force

(a) Except as otherwise provided in subsection (b) of this section, when calculating a member's contribution to their coinsurance, copayment, cost-sharing responsibility, deductible, or out-of-pocket maximum under the member's health benefit plan, the health insurer shall  include any discount, financial assistance payment, product voucher, or any other out-of-pocket expense made by or on behalf of the member for a prescription drug covered under the member's health benefit plan that:
  (1) Is without a generic drug equivalent or an interchangeable biological product preferred under the health benefit plan's formulary; or
  (2) Has a generic equivalent drug or an interchangeable biological product preferred under the health benefit plan's formulary where the member has obtained access to the drug through prior authorization, a step therapy protocol, or the exception or appeal process of the health insurer or pharmacy benefits manager.
(b) Subsection (a) of this section shall not apply to a member covered by a high deductible health plan, as that term is defined under 26 U.S.C. § 223, until the member satisfies their minimum deductible; except, that subsection (a) of this section shall apply to contribution amounts made for preventative care, as that term is defined under 26 U.S.C. § 223(c)(2)(C).
(c) This section shall apply to health benefit plans entered into, amended, extended, or renewed on or after January 1, 2025.
D.C. Code § 48-1102 — DC Code / Title 48 / Chapter 11 / § 48-1102
§ 48-1102. Factors to be considered in determining whether object is paraphernalia.
Status: in_force

(a) In determining whether an object is drug paraphernalia, a court or other authority shall consider, in addition to all other logically and legally relevant factors, the following factors:
  (1) Statements by an owner or by anyone in control of the object concerning its use;
  (2) The proximity of the object, in time and space, to a violation of § 48-1103(a) or to a controlled substance;
  (3) The existence of any residue of a controlled substance on the object;
  (4) Direct or circumstantial evidence of the intent of an owner, or of anyone in control of the object, to deliver it to persons whom he or she knows, or should reasonably know, intends to use the object to facilitate a violation of § 48-1103(a) ; the innocence of an owner, or of anyone in control of the object, as to a violation of § 48-1103(a) shall not prevent a finding that the object is intended for use, or designed for use as drug paraphernalia;
  (5) Instructions, oral or written, provided with the object concerning its use;
  (6) Descriptive materials accompanying the object which explain or depict its use;
  (7) National and local advertising concerning the use of the object;
  (8) The size or packaging of the object, or the manner in which it is displayed;
  (9) Whether the owner, or anyone in control of the object, is a legitimate supplier of like or related items to the community, including, but not limited to, a licensed distributor or dealer of tobacco products;
  (10) Direct or circumstantial evidence of the ratio of sales of the object or objects to the total sales of the business enterprise;
  (11) The existence and scope of legitimate uses for the object in the community; and
  (12) Expert testimony concerning its use.
(b) Where the alleged violation of the act occurred at a commercial retail or wholesale establishment, the court or other authority may infer, based upon consideration of the factors in subsection (a) of this section, that the following items are drug paraphernalia:
  (1) Glassy plastic bags or zip-lock bags that measure 1 inch by 1 inch or less; or
  (2) Metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes, with or without screens, permanent screens, hashish heads, or punctuated metal bowls.
D.C. Code § 48-803.01 — DC Code / Title 48 / Chapter 8 / § 48-803.01
§ 48-803.01. Generically equivalent drug formulary; therapeutic interchange list.
Status: in_force

(a) The formulary of generically equivalent drug products for the District of Columbia shall be the chemical and generic drugs contained in the Food and Drug Administration publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” including all updates issued by the Food and Drug Administration (“Orange Book”).
(b) The Boards of Pharmacy and Medicine may jointly establish a therapeutic interchange list.
(c) If a therapeutic interchange list is established pursuant to subsection (b) of this section:
  (1) The Boards of Pharmacy and Medicine shall:
    (A) Revise or supplement the therapeutic interchange list as necessary;
    (B) Establish procedures to allow a prescriber to consent to the substitution of therapeutically equivalent drug products without prior approval based on the therapeutic interchange list; provided, that a prescriber be allowed to limit authorization to specific conditions or patients and that no prescriber be required for any reason to consent to participation in the therapeutic interchange list; and
    (C) Establish and maintain a database, searchable in real time, of those prescribers who have consented to use of the therapeutic interchange list, including any restrictions based on specific conditions or patients; and
  (2) The Department of Health shall distribute the therapeutic interchange list to all pharmacies licensed in the District and shall publish it regularly in the District of Columbia Register.
(d) The Board of Pharmacy and the Board of Medicine shall maintain a link on their websites to the current list of biological products determined by the FDA to be interchangeable with a specific biological product.
D.C. Code § 48-802.01 — DC Code / Title 48 / Chapter 8 / § 48-802.01
§ 48-802.01. Interference with disclosure of price information prohibited.
Status: in_force

No person may directly or indirectly prohibit, hinder or restrict or attempt to prohibit or restrict the disclosure by any pharmacy, government agency, or other person, of accurate price information regarding prescription drugs, including such disclosure made by means of advertisements in print or broadcast media, or by other means.
D.C. Code § 48-202 — DC Code / Title 48 / Chapter 2 / § 48-202
§ 48-202. Violations.
Status: repealed

Repealed.
D.C. Code § 48-605 — DC Code / Title 48 / Chapter 6 / § 48-605
§ 48-605. Shipment of products into District meeting federal or state specifications.
Status: repealed

Repealed.
D.C. Code § 48-855.02a — DC Code / Title 48 / Chapter 8H / § 48-855.02a
§ 48-855.02a. Insulin copayment or coinsurance limitation.
Status: in_force

(a) A health insurer that provides coverage for prescription insulin drugs pursuant to the terms of a health benefits plan the insurer offers shall limit the total amount that an insured is required to pay for a 30-day supply of covered prescription insulin drugs at an amount not to exceed $30, regardless of the quantity or type of covered prescription insulin drug used to fill the insured's prescription.
(b) A health insurer that provides coverage for diabetes devices and diabetic ketoacidosis devices pursuant to the terms of a health benefits plan offered by the insurer, shall limit the total amount that an insured is required to pay for a 30-day supply of all medically necessary covered diabetes devices and diabetic ketoacidosis devices that are in accordance with the insured's diabetes treatment plan at an amount not to exceed $100.
(c) Pursuant to subsections (a) and (b) of this section, prescription insulin drugs, diabetes devices, and diabetic ketoacidosis devices shall be covered without being subject to a deductible and any cost sharing paid by an insured shall be applied toward the insured's deductible and out of pocket maximum obligations.
(d) Nothing in this section prevents an insurer from reducing an insured's copayment or coinsurance by an amount greater than the amount specified in subsections (a) and (b) of this section.
(e) On July 1 of each year, the limit on a required copayment or coinsurance an insured is required to pay under subsections (a) and (b) of this section shall increase by a percentage equal to the percentage change from the preceding year in the medical care component of the Consumer Price Index for All Urban Consumers, Washington-Arlington-Alexandria, DC-VA-MD-WV metropolitan area, as published by the Bureau of Labor Statistics of the United States Department of Labor.
(f) This section shall apply as of January 1, 2022.
D.C. Code § 48-905.03 — DC Code / Title 48 / Chapter 9 / § 48-905.03
§ 48-905.03. Burden of proof.
Status: in_force

(a) It is not necessary for the prosecution to negate any exemption or exception in this chapter in any complaint, information, indictment, or other pleading or in any trial, hearing, or other proceeding under this chapter. The burden of proof of any exemption or exception is upon the person claiming it.
(b) In the absence of proof that a person is the duly authorized holder of an appropriate registration or order form issued under this chapter, he or she is presumed not to be the holder of the registration or form. The burden of proof is upon him or her to rebut the presumption.
(c) Subsections (a) and (b) of this section shall not apply to D.C. Law 20-278 .
D.C. Code § 48-652 — DC Code / Title 48 / Chapter 6A / § 48-652
§ 48-652. Restrictions on third-party meals delivery platforms.
Status: in_force

(a) A third-party meal delivery platform shall not arrange for the delivery of an order from a restaurant without first obtaining an agreement with the restaurant expressly authorizing the third-party meal delivery platform to collect meal orders and deliver meals prepared by the restaurant.
(b) An agreement shall not include any provision, clause, or covenant that requires a restaurant to indemnify a third-party meal delivery platform, any independent contractor acting on behalf of the third-party meal delivery platform, or any registered agent of the third-party meal delivery service for any damages or harm that may occur after the restaurant's product leaves the restaurant.
(c) (1) A third-party meal delivery platform shall not advertise or otherwise market a telephone number, website, or application software featuring or marketing a restaurant without an agreement.
  (2) Upon expiration or termination of an agreement, the third-party meal delivery platform shall transfer and assign any telephone number and URL for a website used exclusively to advertise or market the restaurant to the restaurant for the restaurant's use.
(d) A third-party meal delivery platform that does not have an agreement shall not use the name, likeness, trademark, or intellectual property of a restaurant on its platform.
(e) Any agreement that a third-party meal delivery platform enters into with a restaurant must contain a provision allowing a food delivery worker to use the restroom facilities of the restaurant when performing a delivery or pickup service at the restaurant.
(f) A third-party meal delivery platform shall not exclude any restaurant with whom the third-party meal delivery platform has an agreement from the relevant search results of a customer within 4 miles of a restaurant.
(g) A third-party meal delivery platform shall not reduce the delivery radius of any restaurant below 4 miles based on the level or percentage of commissions paid. Nothing in this section shall prohibit a third-party meal delivery platform from offering a larger delivery radius for a fee.
(h) A third-party meal delivery platform shall not reduce the number of food delivery workers available to deliver online orders from a restaurant with whom the third-party meal delivery platform has an agreement based solely on the level or percentage of commission paid. Nothing in this section shall prohibit a third-party meal delivery platform from offering priority delivery services for a fee.
D.C. Code § 48-833.06 — DC Code / Title 48 / Chapter 8A / § 48-833.06
§ 48-833.06. Penalty.
Status: in_force

This subchapter may be enforced in a civil action brought by the Corporation Counsel. A manufacturer or labeler that fails to provide a report as required by this subchapter commits a civil violation for which a fine of $1,000 plus costs and attorney’s fees may be adjudged.
D.C. Code § 48-402.01 — DC Code / Title 48 / Chapter 4 / § 48-402.01
§ 48-402.01. Urban Farming Land Lease Program.
Status: in_force

(a) There is established within the Department the Urban Farming Land Lease Program ("Program"), which shall enable a qualified applicant identified pursuant to subsection (c) of this section to enter into a lease agreement with the District to create and maintain an urban farm on vacant land identified pursuant to subsection (b) of this section.
(b) (1) The Department shall, in consultation with the Department of General Services and the Office of Planning and no less frequently than annually, identify vacant land in the inventory of real property assets maintained pursuant to § 10-551.05 , that is suitable for use as an urban farm.
  (2) Before entering into a lease agreement under this section in which the lessee plans to grow produce in the site soil of the leased property, the Department shall test the site soil to determine whether the soil is substantially free of contamination.
(c) To be eligible for the Program, an applicant shall:
  (1) At the time of submission of an application:
    (A) Be a resident of the District; or
    (B) In the case of an applicant that is not an individual, be organized or incorporated in the District;
  (2) Have experience in agricultural production;
  (3) Not be precluded from obtaining a license or permit pursuant to § 47-2862 ; and
  (4) Meet any additional criteria the Department establishes pursuant to the rules issued pursuant to subsection (g) of this section.
(d) A lease agreement entered into pursuant to this section shall, at a minimum:
  (1) Be for a base period of at least 5 years, and may have an option or options for the Department to renew the lease; provided, that no single option period shall have a duration of greater than 5 years and the total lease term, inclusive of all option periods, shall not exceed 14 years;
  (2) Prohibit the sale or consumption of produce grown in the site soil of the leased property if the Department determines that the site soil is not substantially free of contamination;
  (3) Permit the sale on or off the leased property of produce grown in the site soil of the leased property if the Department determines that the site soil is substantially free of contamination; and
  (4) Permit the sale of produce on or off the leased property of produce grown at the property when the lessee:
    (A) Does not plant in or use the site soil, but instead uses, for example, raised beds, greenhouses, or hydroponic towers; and
    (B) Ensures that produce does not come into contact with the site soil.
(e) Property leased pursuant to this section shall be exempt from real property taxation and possessory interest taxation.
(f) The Department shall make available to the public on its website information on the Program, including:
  (1) The list of available vacant land identified pursuant to subsection (b) of this section;
  (2) A list of vacant land currently being leased under the Program; and
  (3) Information on how applicants may apply to the Program.
(g) The Mayor, pursuant to subchapter I of Chapter 5 of Title 2 , may issue rules to implement the provisions of this section.
D.C. Code § 48-902.07 — DC Code / Title 48 / Chapter 9 / § 48-902.07
§ 48-902.07. Schedule III tests.
Status: in_force

The Mayor shall place a substance in Schedule III if the Mayor finds that:
(1) The substance has a potential for abuse less than the substances listed in Schedules I and II;
(2) The substance has currently accepted medical use in treatment in the United States or the District of Columbia; and
(3) The abuse of the substance may lead to moderate or low physical dependence or high psychological dependence.
D.C. Code § 48-853.08 — DC Code / Title 48 / Chapter 8G / § 48-853.08
§ 48-853.08. Immunity from liability.
Status: in_force

(a) The Director and the employees of the Department shall not be liable for any civil damages resulting from the accuracy or inaccuracy of any information reported, compiled, or maintained by the Program pursuant to this chapter.
(b) The Director and the employees of the Department shall not be liable for any civil damages resulting from the disclosure of or failure to disclose any information in compliance with this chapter and the Department’s regulations.
(c) In the absence of gross negligence or willful misconduct, prescribers or dispensers complying in good faith with the reporting requirements of this chapter shall not be liable for any civil damages for any act or omission resulting from the submission of such required reports.
D.C. Code § 48-841.04 — DC Code / Title 48 / Chapter 8B / § 48-841.04
§ 48-841.04. Penalties.
Status: in_force

Failure to comply with this chapter may be used by a health-occupation board as a factor when determining licensure status for a prescriber; provided, that a prescriber shall not be subject to an adverse licensure action if the Board of Medicine determines that the prescribing, administering, or furnishing of the prescription medication for the off-label use was clearly evidence-based and the common practice within the medical community.
D.C. Code § 48-906.01 — DC Code / Title 48 / Chapter 9 / § 48-906.01
§ 48-906.01. Pending proceedings.
Status: in_force

(a) Prosecution for any violation of the laws repealed by D.C. Law 4-29 , pursuant to § 604, which were initiated prior to August 5, 1981, is not affected or abated by this chapter. If the offense being prosecuted is similar to an offense set out in subchapter IV of this chapter , then the penalties under subchapter IV of this chapter apply if they are less than those under prior law.
(b) Civil seizures or forfeitures commenced prior to August 5, 1981, are not affected by this chapter.
(c) All administrative proceedings pending under prior laws which are superseded by this chapter shall be continued and brought to a final determination in accord with the laws and rules in effect prior to August 5, 1981.
(d) The Mayor shall initially permit persons to register who own or operate any establishment engaged in the manufacture, distribution, or dispensing of any controlled substance prior to August 5, 1981, and who are registered or licensed by the District of Columbia on August 5, 1981, pursuant to laws and rules in effect immediately prior thereto.
(e) This chapter applies to violations of law, seizures and forfeiture, administrative proceedings, and investigations which occur following its effective date.
D.C. Code § 48-631 — DC Code / Title 48 / Chapter 6 / § 48-631
§ 48-631. Conflicts of interest of government officers or employees.
Status: repealed

Repealed.
D.C. Code § 48-907.02 — DC Code / Title 48 / Chapter 9 / § 48-907.02
§ 48-907.02. Funding and disbursements.
Status: repealed

Repealed.
D.C. Code § 48-708 — DC Code / Title 48 / Chapter 7 / § 48-708
§ 48-708. Inspections.
Status: in_force

(a) The Mayor shall conduct an on-site inspection of an applicant’s facility before a license is granted.
(b) The Mayor, at any reasonable hour and consistent with constitutional guidelines, may enter a facility to conduct an announced or unannounced inspection of the facility to determine if the facility is in compliance with this chapter, the rules issued pursuant to this chapter, or any other District or locally enforceable federal law applicable to the manufacture, distribution, or wholesale of drugs.
D.C. Code § 48-203 — DC Code / Title 48 / Chapter 2 / § 48-203
§ 48-203. Prosecutions.
Status: repealed

Repealed.
D.C. Code § 48-852.05 — DC Code / Title 48 / Chapter 8F / § 48-852.05
§ 48-852.05. Collection receptacles.
Status: repealed

Repealed.
D.C. Code § 48-1204 — DC Code / Title 48 / Chapter 12 / § 48-1204
§ 48-1204. Substance Abuse Prevention and Treatment Fund.
Status: in_force

(a) There is established as a special fund the Substance Abuse Prevention and Treatment Fund (“Fund”), which shall be administered by the Department of Behavioral Health in accordance with subsections (c) and (d) of this section.
(b) The Fund shall consist of revenue from the payment of fines collected pursuant to § 48-1203 .
(c) The Fund shall be used for substance abuse prevention and treatment efforts.
(d) (1) The money deposited into the Fund, and interest earned, shall not revert to the unrestricted fund balance of the General Fund at the end of a fiscal year, or at any other time.
  (2) Subject to authorization in an approved budget and financial plan, any funds appropriated in the Fund shall be continually available without regard to fiscal year limitation.
D.C. Code § 48-101 — DC Code / Title 48 / Chapter 1 / § 48-101
§ 48-101. Possession or disposition of adulterated articles prohibited.
Status: in_force

No person shall, within the District of Columbia, by himself or by his servant or agent, or as the servant or agent of any other person, sell, exchange, or deliver, or have in his custody or possession with the intent to sell or exchange, or expose or offer for sale or exchange, any article of food or drug which is adulterated within the meaning of this chapter.
D.C. Code § 48-902.02 — DC Code / Title 48 / Chapter 9 / § 48-902.02
§ 48-902.02. Nomenclature.
Status: in_force

The controlled substances listed or to be listed in the schedules in §§ 48-902.04 , 48-902.06 , 48-902.08 , 48-902.10 and 48-902.12 are included by whatever official, common, usual, chemical, or trade name designated.
D.C. Code § 48-921.02 — DC Code / Title 48 / Chapter 9B / § 48-921.02
§ 48-921.02. Search warrants; issuance, execution and return; property inventory; filing of proceedings; interference with service.
Status: in_force

(a) Except as provided in subsection (a-1) of this section, a search warrant may be issued by any judge of the Superior Court of the District of Columbia or by a United States Magistrate for the District of Columbia when any controlled substances are manufactured, possessed, controlled, sold, prescribed, administered, dispensed, or compounded, in violation of the provisions of the District of Columbia Uniform Controlled Substances Act of 1981 [ D.C. Law 4-29 ], and any such controlled substances and any other property designed for use in connection with such unlawful manufacturing, possession, controlling, selling, prescribing, administering, dispensing, or compounding may be seized thereunder, and shall be subject to such disposition as the Court may make thereof and such controlled substances may be taken on the warrant from any house or other place in which they are concealed.
(a-1) A search warrant shall not be issued if the sole basis for its issuance would be the possession or transfer without remuneration of marijuana weighing one ounce or less.
(b) A search warrant cannot be issued but upon probable cause supported by affidavit particularly describing the property and the place to be searched.
(c) The judge or Magistrate must, before issuing the warrant, examine on oath the complainant and any witnesses he may produce, and require their affidavits or take their depositions in writing and cause them to be subscribed by the parties making them.
(d) The affidavits or depositions must set forth the facts tending to establish the grounds of the application or probable cause for believing that they exist.
(e) If the judge or Magistrate is thereupon satisfied of the existence of the grounds of the application or that there is probable cause to believe their existence, he shall issue a search warrant, signed by him, to the Chief of Police of the District of Columbia or any member of the Metropolitan Police Department, the Chief or any member of the District of Columbia Housing Authority Police Department, or the Chief or any member of the United States Park Police, stating the particular grounds or probable cause for its issue and the names of the persons whose affidavits have been taken in support thereof, and commanding the Chief of Police or member of the Metropolitan Police Department, the Chief or member of the District of Columbia Housing Authority Police Department, or the Chief or member of the United States Park Police forthwith to search the place named for the property specified and to bring it before the judge or Magistrate.
(f) A search warrant may in all cases be served by any of the officers mentioned in its direction, but by no other person, except in aid of the officer on his requiring it, he being present and acting in its execution.
(g) The officer may break open any outer or inner door or window of a house, or any part of a house, or anything therein, to execute the warrant, if, after notice of his authority and purpose, he is refused admittance.
(h) The judge or Magistrate shall insert a direction in the warrant that it may be served at any time in the day or night.
(i) A search warrant must be executed and returned to the judge or Magistrate who issued it within 10 days after its date; after the expiration of this time the warrant, unless executed, is void.
(j) When the officer or the designated civilian employee of the Metropolitan Police Department, the District of Columbia Housing Authority Police Department, or the United States Park Police takes property under the warrant, he must give a copy of the warrant together with a receipt for the property taken (specifying it in detail) to the person from whom it was taken by him, or in whose possession it was found; or in the absence of any person, he must leave it in the place where he found the property.
(k) The officer or the designated civilian employee of the Metropolitan Police Department, the District of Columbia Housing Authority Police Department, or the United States Park Police must forthwith return the warrant to the judge or Magistrate and deliver to him a written inventory of the property taken, made publicly or in the presence of the person from whose possession it was taken, and of the applicant for the warrant, if they are present, verified by the affidavit of the officer at the foot of the inventory and taken before the judge or Magistrate at the time, to the following in effect: “I, , the officer by whom this warrant was executed, do swear that the above inventory contains a true and detailed account of all the property taken by me on the warrant.”
________
(l) The judge or Magistrate must thereupon, if required, deliver a copy of the inventory to the person from whose possession the property was taken and to the applicant for the warrant.
(m) The judge or Magistrate must annex the affidavits, search warrant, return, inventory, and evidence, and at once file the same, together with a copy of the record of his proceedings, with the Clerk of the Superior Court of the District of Columbia.
(n) Whoever shall knowingly and willfully obstruct, resist, or oppose any such officer or person in serving or attempting to serve or execute any such search warrant, or shall assault, beat, or wound any such officer or person, knowing him to be an officer or person so authorized, shall be fined not more than the amount set forth in § 22-3571.01 or imprisoned not more than 2 years.
D.C. Code § 48-831.10 — DC Code / Title 48 / Chapter 8A / § 48-831.10
§ 48-831.10. AccessRx Fund.
Status: in_force

(a) The AccessRx Fund is established as a nonlapsing, dedicated fund, into which shall be deposited revenue from manufacturers and labelers that pay rebates pursuant to this subchapter and any appropriations or allocations designated for the AccessRx Fund, along with accruing interest, to be used for the purposes specified in subsection (b) of this section.
(b) All funds in the AccessRx Fund, including any surplus or interest, shall be used to:
  (1) Reimburse retail pharmacies for discounted prices provided to uninsured qualified residents pursuant to § 48-831.33 ;
  (2) Pay benefits described in § 48-831.23 ; and
  (3) Reimburse the Department for contracted services, including pharmacy claims processing fees, administrative and associated computer costs, and other reasonable program costs.
(c) The funds deposited in the AccessRx Fund shall not revert to the General Fund but shall continually be available for the uses designated in subsection (b) of this section, subject to authorization by Congress in an appropriations act.
D.C. Code § 48-301 — DC Code / Title 48 / Chapter 3 / § 48-301
§ 48-301. Immunity from liability.
Status: in_force

(a) All other provisions of law notwithstanding, a good faith donor of food which is not known or believed to be unfit for human consumption, as defined in Chapter 1 of this title , or rules issued pursuant to that chapter at the time it is donated to a bona fide charitable or nonprofit organization or directly to an individual for consumption shall not be subject to criminal or civil liability arising from an injury or death due to the condition of such food unless such injury or death is a direct result of the gross negligence or intentional misconduct of such donor.
(b) All other provisions of law notwithstanding, a bona fide charitable or not-for-profit organization which in good faith receives and distributes food which is not known or believed to be unfit for human consumption, as defined in Chapter 1 of this title , or rules issued pursuant to that chapter at the time it is distributed, without charge or at a charge sufficient to cover the cost of handling and preparing such food, shall not be subject to criminal or civil liability arising from an injury or death due to the condition of such food unless such injury or death is a direct result of the gross negligence or intentional misconduct of such organization.
D.C. Code § 48-903.02 — DC Code / Title 48 / Chapter 9 / § 48-903.02
§ 48-903.02. Registration — Required; renewal; exceptions; waiver; inspection.
Status: in_force

(a) Every person who manufactures, distributes, or dispenses any controlled substance within the District of Columbia, or who proposes to engage in the manufacture, distribution, or dispensing of any controlled substance within the District of Columbia, must obtain annually a registration issued by the Mayor in accordance with the rules. Applications to renew a registration must be filed in a timely manner, not less than 60 days prior to the expiration of the registration, or the registration shall abate.
(b) Persons registered with the Mayor under this chapter to manufacture, distribute, dispense, or conduct research with controlled substances may possess, manufacture, distribute, dispense, or conduct research with those substances to the extent authorized by their registration and in conformity with the other provisions of this subchapter. Any person registered under this subchapter whose authority to possess, distribute, dispense, or conduct research with controlled substances is limited or otherwise restricted by any federal, state, or District of Columbia law, shall use such registration only to the extent authorized by said federal, state, or District of Columbia law unless otherwise specified.
(c) The following persons need not register and may lawfully possess controlled substances under this chapter:
  (1) An agent or employee of any registered manufacturer, distributor, or dispenser of any controlled substance acting in the usual course of business or employment;
  (2) A common or contract carrier or warehouseman, or an employee thereof, whose possession of any controlled substance is in the usual course of business or employment;
  (3) An ultimate user or a person in possession of any controlled substance pursuant to a lawful order of a practitioner or in lawful possession of a Schedule V substance; and
  (4) A designated civilian employee of the Metropolitan Police Department, or a law-enforcement official or agent of the District of Columbia or the United States if he or she is on duty and is acting in the performance of officially authorized functions.
(d) The Mayor may waive by rule the requirement for registration of certain manufacturers, distributors, or dispensers if the Mayor finds it consistent with the public health and safety.
(e) A separate registration is required for each principal place of business or professional practice where the applicant manufactures, distributes, or dispenses controlled substances.
(f) The Mayor may inspect the establishment of a registrant or applicant for registration in accordance with subsections (a) and (b) of this section.
D.C. Code § 48-831.01 — DC Code / Title 48 / Chapter 8A / § 48-831.01
§ 48-831.01. Findings and declaration of intent.
Status: in_force

The Council finds that:
(1) Affordability is critical in providing access to prescription drugs for District of Columbia residents.
(2) AccessRx enables the District to take steps to make prescription drugs more affordable for qualified District residents, thereby increasing the overall health of District residents, promoting healthy communities, and protecting the public health and welfare.
(3) AccessRx can be integrated with any District-wide program for the uninsured.
(4) The intent of AccessRx is not to discourage employers from offering or paying for prescription drug benefits for their employees or to replace employer-sponsored prescription drug benefit plans that provide benefits comparable to those made available to qualified District residents under AccessRx.
D.C. Code § 48-803.03 — DC Code / Title 48 / Chapter 8 / § 48-803.03
§ 48-803.03. Dispensing of substitute drug products — conditions.
Status: in_force

A pharmacist shall not dispense a:
(1) Substitute drug product if the person purchasing the drug product or the patient for whom it is intended indicates a preference for the drug product actually prescribed;
(2) Generically equivalent drug product or interchangeable biological product pursuant to § 48-803.02 if:
  (A) The prescriber writes on a prescription order, signed by the prescriber, in the prescriber’s own handwriting “dispense as written” or “D.A.W.” or a similar notation; provided, that checking or initialing a box preprinted or stamped on a prescription form shall not constitute an acceptable notation; or
  (B) The prescriber, by telephone, expressly indicates that the prescription is to be dispensed as communicated and this indication is noted in the pharmacist’s own handwriting in the manner provided in subparagraph (A) of this paragraph;
(3) (A) Therapeutically equivalent drug product unless:
    (i) (I) The pharmacist or pharmacist’s agent obtains prior approval from the prescriber or the prescriber’s agent before the therapeutically equivalent drug product can be dispensed; or
      (II) The therapeutically equivalent drug product is included on the therapeutic interchange list and the endorsing prescriber has given consent to the Boards of Pharmacy and Medicine to permit therapeutic interchange without prior approval;
    (ii) The person purchasing the drug product provides consent to the therapeutic interchange;
    (iii) The therapeutically equivalent drug product does not have a higher cost to the purchaser than the originally prescribed drug product; provided, that the pharmacist may dispense a more expensive therapeutically equivalent drug product if consent is provided by the purchaser; and
    (iv) The dispensing pharmacist, or pharmacist’s agent, has notified the prescriber or prescriber’s agent of the specific drug and dose dispensed.
  (B) A pharmacist shall not dispense a therapeutically equivalent drug product for a prescription refill of an antipsychotic, antidepressant, chemotherapy, antiretroviral, or immunosuppressive drug but shall dispense the drug as prescribed.
D.C. Code § 48-304 — DC Code / Title 48 / Chapter 3 / § 48-304
§ 48-304. Food donation guide and training.
Status: in_force

(a) The Department of Health, in conjunction with the Office of Waste Diversion within the Department of Public Works, shall create a guide for food donors and donees that includes:
  (1) All food safety regulations that apply to food donations in the District, including liability protections, tax credits, or incentives available to food donors;
  (2) What foods may be donated safely;
  (3) The best practices for storing and handling food donations; and
  (4) A list of organizations in the District that accept food donations.
(b) The Department of Health shall train its employees who are involved in health inspections of businesses that donate food and organizations that receive donated food on the information in the guide developed pursuant to this section.
(c) Within 180 days after February 22, 2019, the Department of Health and the Office of Waste Diversion shall each make the guide available on its website.
D.C. Code § 48-601 — DC Code / Title 48 / Chapter 6 / § 48-601
§ 48-601. Production and shipment of products to conform to local standards.
Status: repealed

Repealed.
D.C. Code § 48-831.09 — DC Code / Title 48 / Chapter 8A / § 48-831.09
§ 48-831.09. Action with regard to nonparticipating manufacturers and labelers.
Status: in_force

(a) The names of manufacturers and labelers who do and do not enter into rebate agreements pursuant to this subchapter are public information. The Department shall release this information to health care providers and the public on a regular basis. The Department also shall publicize participation by manufacturers and labelers that is of particular benefit to the public.
(b) The Department shall impose prior authorization requirements, as permitted by law, in all publicly funded pharmaceutical assistance programs to the extent the Department determines it is appropriate to do so in order to encourage manufacturer and labeler participation in AccessRx, as long as the additional prior authorization requirements remain consistent with the goals of the D.C. Medicaid program and Title 19 of the Social Security Act, approved July 30, 1965 (79 Stat. 343; 42 U.S.C. § 1396 et seq.).
D.C. Code § 48-844.03 — DC Code / Title 48 / Chapter 8E / § 48-844.03
§ 48-844.03. Evaluation.
Status: in_force

(a) Within 60 days of September 30, 2010, the Department of Health shall submit to the Council a comprehensive evaluation on the effectiveness of the SafeRx Amendment Act of 2008, effective March 26, 2008 ( D.C. Law 17-131 ), which shall include:
  (1) The number of individuals licensed to engage in the practice of pharmaceutical detailing since March 26, 2008;
  (2) The number of applicants for licensure to engage in the practice of pharmaceutical detailing not approved by the Board of Pharmacy;
  (3) The number of applicants for licensure to engage in the practice of pharmaceutical detailing for whom the educational requirements were waived;
  (4) An assessment of the appropriateness and efficacy of the continuing education requirements established pursuant to D.C. Law 17-131 ;
  (5) The number of individuals identified as engaging in the practice of pharmaceutical detailing without a license;
  (6) The amount of fines levied against persons charged with engaging in the practice of pharmaceutical detailing without a license;
  (7) The total amount and origin of revenue deposited into the Board of Pharmacy Fund;
  (8) The total amount of funds deposited into the Board of Pharmacy Fund that were used for the administration of the duties of the Board of Pharmacy;
  (9) The number and types of penalties levied for failure to comply with the requirements of off-label use of medication as set forth in § 48-841.03 ;
  (10) The number and amount of fines levied for violations as a result of pharmaceutical companies offering gifts or remuneration in violation of § 48-842.03 ;
  (11) The number of persons who participated in the Pharmaceutical Education Program established by § 48-843.03 ;
  (12) An assessment of the quality and effectiveness of the Pharmaceutical Education Program based on an assessment of data gathered from those who participated in the program. The data may be gathered by surveying those who participated in the program, using an evaluative instrument developed for that purpose;
  (13) An assessment of the extent to which regulation of the practice of pharmaceutical detailing has improved the practice of selling, providing information about, or promoting a pharmaceutical product.
(b) The evaluation may be used to determine if D.C. Law 17-131 should be repealed or amended.
D.C. Code § 48-842.01 — DC Code / Title 48 / Chapter 8C / § 48-842.01
§ 48-842.01. Short title.
Status: in_force

This chapter may be cited as the “Medication Advisory Committee Receiving Gifts or Remuneration Prohibition Act of 2008”.
D.C. Code § 48-833.08 — DC Code / Title 48 / Chapter 8A / § 48-833.08
§ 48-833.08. Report.
Status: in_force

The Department shall report to the committee of the Council having jurisdiction over health and human services matters on or before January 1, 2005 and on or before July 1, 2005 on the assessment of fees on manufacturers and labelers of prescription drugs.
D.C. Code § 48-1104 — DC Code / Title 48 / Chapter 11 / § 48-1104
§ 48-1104. Property subject to forfeiture.
Status: in_force

(a) The following shall be subject to forfeiture immediately, and no property right shall exist in them after a final conviction by a court:
  (1) All books, records, and research, including formulas, microfilm, tapes, and data which are used, or intended for use, in violation of this subchapter;
  (2) All money or currency which shall be found in close proximity to drug paraphernalia or which otherwise has been used or intended for use in connection with the manufacture, distribution, delivery, sale, use (other than for personal use), dispensing, or possession (other than for personal use) of drug paraphernalia in violation of § 48-1103 ; and
  (3) All drug paraphernalia as defined in §§ 48-1101 and 48-1102 and prohibited in § 48-1103 .
(b) Repealed.
D.C. Code § 48-833.05 — DC Code / Title 48 / Chapter 8A / § 48-833.05
§ 48-833.05. Confidentiality; public information.
Status: in_force

Notwithstanding any provision of law to the contrary, information submitted to the Department pursuant to this subchapter is confidential and is not a public record. Data compiled in aggregate form by the Department for the purposes of reporting required by this subchapter is a public record as long as it does not reveal trade information that is protected by District, state, or federal law.
D.C. Code § 48-801.02 — DC Code / Title 48 / Chapter 8 / § 48-801.02
§ 48-801.02. Posters to be furnished pharmacies; contents.
Status: in_force

Ten days prior to each issue date, the Office of Consumer Protection shall furnish to each pharmacy in the District a poster suitable for display of a type style and size so as to be easily readable at a reasonable distance, which:
(1) Lists the 100 most commonly used prescription drugs in 2 commonly prescribed quantities, with space for the current selling price of each quantity;
(2) Lists professional and convenience services, with space for each pharmacy to indicate:
  (A) Whether it offers each service; and
  (B) The additional charge, if any, for that service;
(3) Contains a heading stating “OUR CURRENT PRESCRIPTION PRICES” and containing spaces for the insertion of the name and address of each pharmacy;
(4) Indicates in simple language that:
  (A) The price of a prescription drug is often different at different pharmacies, and that the consumer may want to make a comparison on the cost of a prescription;
  (B) The pharmacy may be able to substitute a less expensive drug which is therapeutically equivalent to the one prescribed by the consumer’s doctor, unless the consumer does not approve; and
  (C) The consumer has the right to know the exact price of a prescription before it is filled; and
(5) Provides space for each pharmacy to indicate the eligibility and terms of any discount it offers on legend drugs.
D.C. Code § 48-602 — DC Code / Title 48 / Chapter 6 / § 48-602
§ 48-602. Definitions.
Status: repealed

Repealed.
D.C. Code § 48-902.04 — DC Code / Title 48 / Chapter 9 / § 48-902.04
§ 48-902.04. Schedule I enumerated.
Status: in_force

The controlled substances listed in this section are included in Schedule I, unless and until removed therefrom pursuant to § 48-902.01 :
(a) (1) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
    (A) Acetylmethadol;
    (B) Allylprodine;
    (C) Alphacetylmethadol (except levo-alphacetylmethadol, also known as levo-alphaacetylmethadol, levomethadyl, accetate, or LAAM);
    (D) Alphameprodine;
    (E) Alphamethadol;
    (F) Benzethidine;
    (G) Betacetylmethadol;
    (H) Betameprodine;
    (I) Betamethadol;
    (J) Betaprodine;
    (K) Clonitazene;
    (L) Dextromoramide;
    (M) Diampromide;
    (N) Diethylthiambutene;
    (O) Difenoxin;
    (P) Dimenoxadol;
    (Q) Dimepheptanol;
    (R) Dimethylthiambutene;
    (S) Dioxaphetylbutyrate;
    (T) Dipipanone;
    (U) Ethylmethylthiambutene;
    (V) Etonitazene;
    (W) Etoxeridine;
    (X) Furethidine;
    (Y) Hydroxypethidine;
    (Z) Ketobemidone;
    (AA) Levomoramide;
    (BB) Levophenacylmorphan;
    (CC) Morpheridine;
    (DD) Noracymethadol;
    (EE) Norlevorphanol;
    (FF) Normethadone;
    (GG) Norpipanone;
    (HH) Phenadoxone;
    (II) Phenampromide;
    (JJ) Phenomorphan;
    (KK) Phenoperidine;
    (LL) Piritramide;
    (MM) Proheptazine;
    (NN) Properidine;
    (OO) Propiram;
    (PP) Racemoramide;
    (QQ) Thiophene;
    (RR) Trimeperidine;
    (SS) Acetyl-Alpha-Methylfentanyl;
    (TT) Alphe-methylfentanyl;
    (UU) Alpha-Methylthiofentanyl;
    (VV) Beta-hydroxyfentanyl;
    (WW) Beta-hydroxy-3-Methylfentanyl;
    (XX) 3-Methylfentanyl;
    (YY) 3-Methylthiofentanyl;
    (ZZ) MPPP;
    (AAA) Para-flurofentanyl;
    (BBB) PEPAP;
    (CCC) Thiofentanyl; and
    (DDD) Tilidine;
  (2) Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
    (A) Acetorphine;
    (B) Acetyldihydrocodeine;
    (C) Benzylmorphine;
    (D) Codeine methylbromide;
    (E) Codeine-N-Oxide;
    (F) Cyprenorphine;
    (G) Desomorphine;
    (H) Dihydromorphine;
    (I) Drotepanol;
    (J) Etorphine (except hydrochloride salt);
    (K) Diacetylated morphine (heroin);
    (L) Hydromorphinol;
    (M) Methyldesorphine;
    (N) Methyldihydromorphine;
    (O) Morphine methylbromide;
    (P) Morphine methylsulfonate;
    (Q) Morphine-N-Oxide;
    (R) Myrophine;
    (S) Nicocodeine;
    (T) Nicomorphine;
    (U) Normorphine;
    (V) Pholcodine; and
    (W) Thebacon;
  (3) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, its salts, isomers and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation :
    (A) 4-bromo-2, 5-dimethoxyamphetamine;
    (B) 2, 5 dimethoxyamphetamine;
    (C) 4-methoxyamphetamine;
    (D) 5-methoxy-3, 4-methylenedioxy amphetamine;
    (E) 4-methyl-2,5-dimethoxyamphetamine;
    (F) 3,4-methylenedioxyamphetamine [MDA];
    (G) 3, 4, 5-trimethoxy amphetamine;
    (G-i) 25I-NBOMe (also known as 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine);
    (G-ii) 25B-NBOMe (also known as 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine)
    (G-iii) 25C-NBOMe (also known as 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);
    (G-iv) 5-APB (also known as α-methyl-5-benzofuranethanamine);
    (G-v) 5-APDB (also known as 2,3-dihydro-α-methyl-5-benzofuranethanamine);
    (G-vi) 6-APB (also known as α-methyl-6-benzofuranethanamine);
    (G-vii) 6-APDB (also known as 2,3-dihydro-α-methyl-6-benzofuranethanamine);
    (G-viii) 3-methoxy-PCE (also known as N-ethyl-1-(3-methoxyphenyl)-cyclohexanamine);
    (G-ix) 3-methoxy-PCP (also known as 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine);
    (G-x) 4-methoxy-PCP (also known as 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine);
    (G-xi) 5-methoxy-DALT, also known as:
      (i) 5-MeO-DALT; or
      (ii) 5-methoxy-N,N-di-2-propen-1-yl-1H-indole-3-ethanamine;
    (G-xii) 4-acetoxy DMT, also known as:
      (i) 4-AcO-DMT; or
      (ii) 3-[2-(dimethylamino)ethyl]-1H-indol-4-ol-4-acetate;
    (H) Bufotenine;
    (I) Diethyltryptamine;
    (J) Dimethyltryptamine;
    (K) Ethylamide analog of phencyclidine, PCE;
    (L) Ibogaine;
    (M) Lysergic acid diethylamide;
    (M-i) Methoxetamine (also known as 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone);
    (N) Mescaline;
    (O) Peyote;
    (P) N-ethyl-3-piperidyl benzilate;
    (Q) N-methyl-3-piperidyl benzilate;
    (R) Psilocybin;
    (S) Psilocyn;
    (T) Pyrrolidine analog of phencyclidine, PCPY;
    (U) Thiophene analog of phencyclidine;
    (V) Repealed;
    (W) Parahexyl;
    (X) 4-bromo-2,5-dimethoxyphenethylamine;
    (Y) 3,4-methylenedioxymethamphetamine [MDMA];
    (Z) Alpha-methyltryptamine (other name: AMT);
    (AA) 5-methoxy-N,N-diisopropyltryptamine (other name: 5- MeO-DIPT);
    (BB) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);
    (CC) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
    (DD) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
    (EE) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
    (FF) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
    (GG) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
    (HH) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C- T-4);
    (II) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
    (JJ) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
    (KK) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); and
    (LL) Cathinone;
  (4) Unless specifically excepted or unless listed in another schedule, any material, compound, or mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
    (A) Mecloqualone;
    (B) Methaqualone; and
    (C) Gamma-hydroxybutyric acid (some other names include GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);
  (5) As used in this paragraph, the term "synthetic cathinones" includes any material, compound, mixture, or preparation that is not otherwise listed as a controlled substance in this schedule or in Schedules II through V, is not approved by the Food and Drug Administration as a drug, and is structurally derived from or contains any quantity of the following substances, their salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues, unless specifically excepted, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:
    (A) Classified Synthetic Cathinones:
      (i) Cathinones. Any compound, other than methylnenedioxy cathinones and pyrrolidine cathinones, containing a 2-amino-1-propanone structure with substitution at the 1-position with a monocyclic ring system, with or without alkyl, alkoxyl, or halo substitutions, and a substitution at the nitrogen atom by an alkyl group, cycloalkyl group, or incorporation into a heterocyclic structure. Examples of this structural class include:
        (I) Mephedrone, also known as:
          (aa) 2-(methylamino )-1-(4-methylphenyl)-1-propanone;
          (bb) 4-MeMC;
          (cc) 4-Methylmethcathinone;
          (dd) 4-Methylephedrone; or
          (ee) 4-MMC;
        (II) Dimethylcathinone, also known as:
          (aa) 2-(dimethylamino)-1-phenyl-1-propanone; or
          (bb) N,N-Dimethylcathinone;
        (III) Ethcathinone, also known as:
          (aa) 2-(ethylamino)-1-phenyl-1-propanone;
          (bb) Ethylcathinone;
          (cc) N-Ethylcathinone; or
          (dd) 2-Ethylaminobuphedro;
        (IV) Buphedrone, also known as:
          (aa) 2-(methylamino)-1-phenylbutan-l-one; or
          (bb) MABP;
        (V) 3,4-DMMC, also known as:
          (aa) 1-(3,4-dimethylphenyl)-2-(methylamino)-1- propanone; or
          (bb) 3,4-Dimethylmethcathinone;
        (VI) EMC, also known as:
          (aa) 1-(4-ethylphenyl)-2-(methylamino)propan-1-one;
          (bb) 4-EMC; or
          (cc) 4-Ethylmethcathinone;
        (VII) Fluoromethcathinone (also known as 1-(4-fluorophenyl)-2-(methylamino) propan-1-one);
        (VIII) 3-FMC, also known as:
          (aa) 3-fluoro-N-methylcathinone); or
          (bb) 1-(3-fluorophenyl)-2-(methylamino)propan-1- one;
        (IX) 4-FMC, also known as:
          (aa) 1-(4-fluorophenyl)-2-(methylamino)propan-1-one;
          (bb) 4-fluoro-N-methylcathinone; or
          (cc) Flephedrone;
        (X) 4-MeBP, also known as:
          (aa) 2-(methylamino)-1-(4-methylphenyl)-1-butanone;
          (bb) 4-Methylbuphedrone;
          (cc) 4-methyl BP; or
          (dd) 4-MeMABP;
        (XI) 3-MEC, also known as:
          (aa) 2-(ethylamino )-1-(m-tolyl)propan-l-one; or
          (bb) 3-Methyl-N-ethylcathinone;
        (XII) 4-MEC, also known as:
          (aa) 2-(ethylamino)-1-(4-methylphenyl)-1-propanone; or
          (bb) 4-Methyl-N-ethylcathinone;
        (XIII) 3-MMC, also known as:
          (aa) 2-(methylamino)-1-(3-methylphenyl)-1-propanone;
          (bb) 3-methyl MS; or
          (cc) 3-Methylmethcathinone;
        (XIV) Methedrone (also known as l-(4-methoxyphenyl)-2-(methylamino)-1-propanone); and
        (XV) Pentedrone (also known as 2-(methylamino)-1-phenylpentan-1-one);
      (ii) Methylenedioxy Cathinones. Any compound containing a 2- amino-1-propanone structure with substitution at the 1-position with a monocyclic or fused polycyclic ring system and a substitution at any position of the ring system with an alkyl, haloalkyl, halogen, alkylenedioxy, or alkoxy group, whether or not further substituted at any position on the ring system to any extent. Examples of this structural class include:
        (I) 3-fluoromethylone;
        (II) Methylone, also known as
          (aa) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-propanone; or
          (bb) 3,4-Methylenedioxy-N-methylcathinone);
        (III) N-ethyl Pentylone, also known as:
          (aa) Ephylone; or
          (bb) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone;
        (IV) bk-MDDMA, also known as:
          (aa) 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one;
          (bb) Dimethylone;
          (cc) N, N -dimethyl-3',4'-methylenedioxycathinone;
          (dd) N, N -dimethyl-3,4-methylenedioxycathinone; or
          (ee) N,N-Dimethyl MDCATH;
        (V) Butylone, also known as 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one); and
        (VI) Ethylone, also known as:
          (aa) 3,4-Methylenedioxy-N-ethylcathinone; or
          (bb) MDEC;
      (iii) Pyrrolidine Cathinones. Any compound containing a 2-amino-1-propanone structure with substitution at the 1-position with an alkyl, cyclic, or fused polycyclic ring system and a substitution at the 3-position carbon with an alkyl, haloalkyl, halogen, alkoxy or alkylenedioxy group, and a substitution at the nitrogen atom incorporation into a heterocyclic structure, with or without further halogen substitutions. Examples include:
        (I) α-PVP (also known as α-pyrrolidinopentiophenone);
        (II) α-pyrrolidinopropiophenone, also known as:
          (aa) 1-phenyl-2-(1-pyrrolidinyl)-l-propanone; or
          (bb) α-PPP;
        (III) α-PBP, also known as:
          (aa) 1-phenyl-2-(1-pyrrolidinyl)-1-butanone; or
          (bb) α-pyrrolidinobutiophenone;
        (IV) MDPBP, also known as:
          (aa) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-butanone;
          (bb) 3,4-Methylenedioxy-α-Pyrrolidinobutiophenone; or
          (cc) 3,4-MDPBP;
        (V) MDPPP, also known as:
          (aa) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-propanone; or
          (bb) 3,4-Methylenedioxy-α-Pyrrolidinopropiophenone;
        (VI) MDPV, also known as:
          (aa) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone; or
          (bb) 3,4-Methylenedioxy Pyrovalerone;
        (VII) 4-MePPP, also known as
          (aa) 4'-methyl-α-Pyrrolidinopropiophenone;
          (bb) 4'-methyl PPP; or
          (cc) 2-(pyrrolidin-l-yl)-1-(p-tolyl)propan-l-one;
        (VIII) 4'-methyl PHP, also known as:
          (aa) 4'-methyl-α-pyrrolidinohexanophenone;
          (bb) MPHP;
          (cc) 4'-methyl-α-PHP; or
          (dd) PV4;
        (IX) Naphyrone, also known as:
          (aa) (RS)-1-naphthalen-2-yl-2-pyrrolidin-l- ylpentan-1-one; or
          (bb) Naphpyrovalerone; and
        (X) C-PVP, also known as:
          (aa) 4-Chloro-α-PVP; or
          (bb) 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan- 1-one; or
      (iv) Piperazine Stimulants. Any compound containing or structurally derived from a piperazine, or diethylenediamine, structure with or without substitution at one of the nitrogen atoms of the piperazine ring to any extent, including alkyl, cycloalkyl, or fused ring systems, with or without further halogen substitutions. Examples include:
        (I) BZP, also known as:
          (aa) 1-(phenylmethyl)-piperazine;
          (bb) 1-Benzylpiperazine; or
          (cc) N-Benzylpiperazine; and
        (II) TMFPP, also known as:
          (aa) 1-[3-(trifluoromethyl)phenyl]-piperazine;
          (bb) 1-(m-Trifluoromethylphenyl) piperazine; or
          (cc) 3-Trifluoromethylphenylpiperazine.
    (B) Unclassified Synthetic Cathinones:
      (i) Aminorex (also known as (RS)-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine);
      (ii) α-ET, also known as:
        (I) α-ethyl-1H-indole-3-ethanamine;
        (II) α-ethyltryptamine; or
        (III) 3-Indolybutylamine;
      (iii) α-MT, also known as:
        (I) α-methyl-1H-indole-3-ethanamine; or
        (II) α-methyltryptamine;
      (iv) EMA, also known as:
        (I) N-ethyl-α-methyl-benzeneethanamine; or
        (II) N-Ethylamphetamine;
      (v) Fenethylline (also known as (RS)-1,3-dimethyl-7-[2-(1-phenylpropan-2-ylamino)ethyl]purine-2,6-dione);
      (vi) N-hydroxy MDA, also known as:
        (I) MDOH;
        (II) N-hydroxy-α-methyl-1,3-benzodioxole-5-ethanamine;
        (III) N-Hydroxy-3,4-methylenedioxyamphetamine; and
      (vii) N,N-DMA, also known as:
        (I) N,N,α-trimethyl-benzeethanamine;
        (II) N,N-Dimethylamphetamine;
        (III) Dimetamfetamine; or
        (IV) Metrotonin.
  (6) Synthetic cannabimimetic agents (also known as "synthetic cannabinoids"), which includes, unless specifically exempted, unless listed in another schedule, or unless approved by the Food and Drug Administration as a drug, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, its salts, isomers, homologues, analogues and salts of isomers, homologues, and analogues, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:
    (A) Classified Synthetic Cannabimimetic Agents:
      (i) Adamantanoylindoles: Any compound containing or structurally derived from  an adamantanyl-(1H-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Examples include:
        (I) AB-001, also known as:
          (aa) (1s,3s)-adamantan-1-yl(1-pentyl-1H-indol-3-yl)methanone; or
          (bb) JWH 018 adamantyl analog; and
        (II) AM-1248, also known as:
          (aa) [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]tricyclo[3.3.1.13,7]dec-1-yl-methanone; or
          (bb) AM1248;
      (ii) Benzimidazole Ketone: Any compound containing or structurally derived from (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.  Benzimidazole Ketones include:
        (I) FUBIMINA, also known as:
          (aa) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone; or
          (bb) AM2201 benzimidazole analog; and
        (II) JWH-018 benzimidazole analog, also known as:
          (aa) naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-yl)methanone; or
          (bb) BIM-018;
      (iii) Benzoylindoles: Any compound containing or structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples include:
        (I) AM-630, also known as:
          (aa) [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanone;
          (bb) AM630; or
          (cc) Iodopravadoline ;
        (II) AM-661 (also known as 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole);
        (III) AM-679, also known as:
          (aa) (2-iodophenyl)(1-pentyl-1H-indol-3-yl)methanone; or
          (bb) AM679;
        (IV) AM-694, also known as:
          (aa) [1-(5-fluoropentyl)-1H-indol-3-yl](2-iodophenyl)-methanone;
          (bb) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; or
          (cc) AM694;
        (V) AM-1241, also known as:
          (aa) (2-iodo-5-nitrophenyl)-(1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl)methanone; or
          (bb) AM1241;
        (VI) AM-2233, also known as:
          (aa) (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-methanone; or
          (bb) AM2233;
        (VII) RCS-4, also known as:
          (aa) (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone; or
          (bb) SR-19; and
        (VIII) WIN 48,098, also known as
          (aa) (4-methoxyphenyl)[2-methyl]-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-methanone; or
          (bb) "Pravadoline";
      (iv) Carbazole Ketone: Any compound containing or structurally derived from (9H-carbazole-3-yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Examples include EG-018 (also known as naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone);
      (v) Indazole Amide: Any compound containing or structurally derived from 3-carboxamide-lH-indazoles, whether or not substituted in the indazole ring to any extent and substituted to any degree on the carboxamide nitrogen and 3-carboxamide-1H-indoles, whether or not substituted in the indole ring to any extent and substituted to any degree on the carboxamide nitrogen. Examples include:
        (I) AB-CHMINACA (also known as N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);
        (II) AB-FUBINACA (also known as N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide);
        (III) AB-PINACA (also known as N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide);
        (IV) 5F AB-PINACA, also known as:
          (aa) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); or
          (bb) 5-fluoro AB-PINACA;
        (V) ADB-FUBINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1-H-indazole-3-carboxamide);
        (VI) ADB-PINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-l-pentyl-1H-indazole-3-carboxamide);
        (VII) 5F ADB-PINACA, also known as:
          (aa) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); or
          (bb) 5-fluoro ADB-PINACA;
        (VIII) FUB-AMB, also known as:
          (aa) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate;
          (bb) AMB-FUBINACA; or
          (cc) MMB-FUBINACA;
        (IX) 5-fluoro-AMB (also known as (S)-methyl 2-(1-(5-fluoropentyl)-lH-indazole-3-carboxamido)-3-methylbutanoate);
        (X) MAB-CHMINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide );
        (XI) MMB CHMINACA, also known as:
          (aa) methyl (S)-2-(l-(cyclohexylmethyl)-IH-indole-3-carboxamido )-3,3-dimethylbutanoate; or
          (bb) MDMB-CHMICA;
        (XII) 5F MN-18, also known as:
          (aa) 1-(5-fluoropentyl)-N-1-naphthalenyl-IH-indazole-3-carboxamide; or
          (bb) 5-fluoro MN-18;
        (XIII) 5F-APINACA, also known as:
          (aa) 5-fluoro-APINACA
          (bb) 5F-AKB-48;
          (cc) 5F-AKB48;
          (dd) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; or
          (ee) N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); and
        (XIV) APINACA, also known as:
          (aa) AKB-48;
          (bb) AKB48;
          (cc) 1-pentyl-N-tricyclo[3.3.l .13,7]dec-1-yl-1H-indazole-3-carboxamide; or
          (dd) N-(1-adamantyl)-1-pentyl-l H -indazole-3-carboxamide;
      (vi) Cyclohexylphenols: Any compound containing or structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the cyclohexyl ring to any extent.  Examples include:
        (I) CP 47,497 (also known as 2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol);
        (II) CP 47,497 C8 homologue, also known as:
          (aa) rel-2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol; or
          (bb) Cannabicyclohexanol;
        (III) CP 55,490;
        (IV) CP 55,940 (also known as 5-(1,1-dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol); and
        (V) CP 56,667;
      (vii) Cyclopropanoylindoles: Any compound containing or structurally derived from 3-(cyclopropylmethanoyl)indole, 3-(cyclopropylmethanone)indole, 3-(cyclobutylmethanone)indole or 3-(cyclopentylmethanone)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, and whether or not substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent. Cyclopropanoylindoles include cyclopropylmethanone indoles, as well as other cycloalkanemethanones, whether or not substituted at the nitrogen atom on the indole ring, whether or not further substituted in the indole ring to any extent, and whether or not substituted on the cycloalkane ring to any extent. Examples of this structural class include:
        (I) A-796,260, also known as:
          (aa) [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or
          (bb) A-796260;
        (II) A-834,735, also known as:
          (aa) [1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or
          (bb) A-834735;
        (III) AB-034 (also known as [1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone);
        (IV) UR-144 (also known as 1-pentyl-3-(2, 2, 3, 3-tetramethylcyclopropoyl)indole);
        (V) 5-bromo-UR-144, also known as:
          (aa) ​[1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or
          (bb) UR-144 N-(5-bromopentyl) analog;
        (VI) 5-chloro-UR-144, also known as:
          (aa) 1-(5-chloropentyl)-3-(2, 2, 3, 3-tetramethylcyclopropoyl)indole; or
          (bb) 5Cl-UR-144;
        (VII) XLR11, also known as:
          (aa) 1-(5-fluoropentyl)-3-(2,2,3, 3-tetramethylcyclopropoyl)indole;
          (bb) 5-FUR-144; or
          (cc) 5-fluoro UR-144; and
        (VIII) FUB-144 (also known as [1-(4-Fluorobenzyl)-lH-indol-3-yl](2,2,3 ,3-tetramethylcyclopropyl)methanone);
      (viii) Hexahydrodibenzopyrans: Any compound containing or structurally derived from Hexahydrodibenzopyrans, whether or not substituted in the tricyclic ring system, except where contained in cannabis or cannabis resin;
      (ix) Indazole Ester (also known as Carboxylate indazole): Any compound containing or structurally derived from 3-carboxylate-indazoles, whether or not substituted in the indazole ring to any extent or substituted to any degree on the carboxylate, whether or not substituted to any extent in the indazole ring or on the carboxylate oxygen. Examples of indazole esters include 5-fluoro SDB-005, also known as:
        (I) naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate; or
        (II) 5F SDB-005;
      (x) Indole Amides: Any compound containing or structurally derived from or containing a 1H-Indole-3-carboxamide structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxamide group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole amides include:
        (I) Adamantylamidoindoles, or any compound containing or structurally derived from an N-(adamantyl)-indole-3-carboxamide structure, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent;
        (II) Adamantylindoles, or any compound containing or structurally derived from an N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the adamantyl ring to any extent;
        (III) 5F ABICA, also known as:
          (aa) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;
          (bb) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; or
          (cc) 5-fluoro ABICA;
        (IV) ADBICA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide));
        (V) 5F-ADBICA, also known as:
          (aa) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; or
          (bb) 5-fluoro-ADBICA;
        (VI) NNE1 (also known as N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
        (VII) 5F-NNE1, also known as:
          (aa) 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide); or
          (bb) 5-fluoro-NNE1;
        (VIII) SDB-006 (also known as N-benzyl-1-pentyl-1H- indole-3-carboxamide);
        (IX) 5F-SDB-006, also known as:
          (aa) N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide); or
          (bb) 5-fluoro-SDB-006;
        (X) 2NE 1, also known as:
          (aa) APICA;
          (bb) JWH 018 adamantyl carboxamide; or
          (cc) 1-pentyl-N-tricyclo[3.3. l .13, 7]dec-1-yl-1H-indole-3-carboxamide;
        (XI) STS-135, also known as:
          (aa) 1-(5-fluoropentyl)-N-tricyclo[3.3. l. l 3, 7]dec-1-yl-l H-indole-3-carboxamide;
          (bb) N-adamantyl-l-fluoropentylindole-3-Carboxamide;
          (cc) 5F-APICA; or
          (dd) 5-fluoro-APICA;
        (XII) SDB-006 (also known as N-benzyl-1-pentyl-lH-indole-3-carboxamide); and
        (XIII) 5-fluoro-MDMB-PICA (also known as N-[[1-(5-fluoropentyl)-1H-indol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester);
      (xi) Indole Esters: Any compound containing or structurally derived from a 1H-Indole-3-carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole esters may also be referred to as Quinolinylindolecarboxylates. Indole esters include:
        (I) Quinolinyl ester indoles, or any compound containing or structurally derived from Quinolinyl ester indoles, being any compound containing or structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl ester, whether or not substituted in the indole ring to any extent or the quinolone ring to any extent;
        (II) BB-22, also known as:
          (aa) 1-(cyclohexylmethyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid;
          (bb) quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate; or
          (cc) QUCHIC;
        (III) FDU-PB-22 (also known as naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);
        (IV) FUB-PB-22, also known as:
          (aa) 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylic acid, 8-quinolinyl ester; or
          (bb) Quinolin-8-yl 1-(4-fluorobenzyl)-1 H -indole-3-carboxylate;
        (V) NM2201, also known as:
          (aa) naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; or
          (bb) CBL-2201;
        (VI) PB-22, also known as:
          (aa) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid;
          (bb) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;
          (cc) 8-Quinolinyl 1-pentyl-1H-indole-3-carboxylate; or
          (dd) "QUPIC"; and
        (VII) 5F-PB-22, also known as:
          (aa) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid;
          (bb) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;
          (cc) 8-Quinolinyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;
          (dd) 5-fluoro-PB-22; or
          (ee) 5-fluoro QUPIC;
      (xii) Naphthoylindoles: Any compound containing or structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the naphthyl ring to any extent, including the following: AM-678, AM-1220, AM-1221, AM-1235, AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011, JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022, JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080, JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH-116, JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166, JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH-234, JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413, JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55-212. Napthoylindoles also include:
        (I) AM-2201 (also known as (1-(5-fluoropentyl)-3-(1-naphthoyl)indole); and
        (II) WIN 55,212-2, also known as:
          (aa) (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone; or
          (bb) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone);
      (xiii) Naphthoylnaphthalenes: Any compound containing or structurally derived from naphthalene-1-yl-(naphthalene-1-yl) methanone with substitutions on either of the naphthalene rings to any extent. Naphthoylnaphthalenes include CB-13 (also known as CRA-13 or 1-naphthalenyl[4-(pentylox)-1-naphthalenyl]-methanone);
      (xiv) Naphthoylpyrroles: Any compound containing or structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-030, JWH-031, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH-245, JWH-246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346, JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH-373, JWH-392;
      (xv) Naphthylamidoindoles: Any compound containing or structurally derived from a N-(naphthyl)-indole-3-carboxamide structure, whether or not further substituted to any extent in the indole ring or in the naphthyl ring;
      (xvi) Naphthylmethyl Indoles: Any compound containing orstructurally derived from 1H-indol-3-yl-(1-naphthyl)methane structure, also known as napthylmethylindoles, with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2- (4-morpholinyl)ethyl group, or 1-(N-methyl-2-pyrrolidinyl)methyl, l-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent. Examples of this structural class include:
        (I) JWH-175 (also known as 3-(1-naphthalenylmethyl)-1-pentyl-1 H-indole );
        (II) JWH-184 (also known as 3-[(4-methyl-1-naphthalenyl)methyl)-1-pentyl-l H-indole);
        (III) JWH-185 (also known as 3-[(4-methoxy-1-naphthalenyl)methyl]-1 -pentyl-1 H-indole);
        (IV) JWH-192 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethane);
        (V) JWH-194 (also known as 2-methyl-1-pentyl-lH-indol-3-yl-( 4-methyl-1-naphthyl)methane);
        (VI) JWH-195 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethane);
        (VII) JWH-196 (also known as 2-methyl-3-(1-naphthalenylmethyl)-1-pentyl-lH-Indole);
        (VIII) JWH-197 (also known as 2-methyl-l-pentyl-lH-indol-3-yl-( 4-methoxy-1-naphthyl)methane); and
        (IX) JWH-199 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethane);
      (xvii) Naphthylmethylindenes: Any compound containing or structurally derived from a naphthylideneindene structure or that is structurally derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-( 4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples include:
        (I) JWH-171;
        (II) JWH-176 (also known as 1-[(E)-(3-pentyl-1 H-inden-1-ylidene)methyl]-naphthalene); and
        (III) JWH-220;
      (xviii) Phenylacetylindoles: Any compound containing or structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including: JWH-167, JWH-201, JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207, JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250, JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305, JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315, JWH-316, RCS-8, SR-18, and Cannabipiperidiethanone (also known as 2-(2-methoxyphenyl)-1-[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-ethanone);
      (xix) Quinolinoyl pyrazole: Any compound containing or structurally derived from Quinolinoyl pyrazole carboxylate (also known as Quinolinyl fluoropentyl fluorophenyl pyrazole carboxylate);
      (xx) Tetrahydrobenzochromen: Any compound containing or structurally derived from (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Includes tetrahydrodibenzopyrans, or any compound containing or structurally derived from tetrahydrodibenzopyrans, whether or not substituted in the tricyclic ring system, but does not include tetrahydrodibenzopyrans that are contained in cannabis or cannabis resin. Examples of this structural class include:
        (I) AM-087 (also known as (6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)- 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);
        (II) AM-411 (also known as (6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);
        (III) HU-210, also known as:
          (aa) 3-(1,1'-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol;
          (bb) [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol;
          (cc) 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol; or
          (dd) 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol;
        (IV) HU-211, also known as:
          (aa) 3-(1,1-dimethylheptyl)-6aS,7,10,10aS-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol;
          (bb) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
          (cc) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or
          (dd) "Dexanabinol";
        (V) HU-243, also known as
          (aa) (6aR,8S,9S,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol; or
          (bb) 3-dimethylheptyl-11-hydroxyhexahydrocannabinol;
        (VI) JWH-051 (also known as (6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl)methanol);
        (VII) JWH-133 (also known as (6aR,10aR)-3-(1,1-Dimethylbutyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran); and
        (VIII) JWH-359 (also known as (6aR,10aR)- 1-methoxy-6,6,9-trimethyl- 3-[(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene);
      (xxi) Δ8 Tetrahydrocannabinol: Any compound containing or structurally derived from 11-hydroxy-Δ8-tetrahydrocannabinol structure, also known as dibenzopyrans, with further substitution on the 3-pentyl group by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkyethyl, 1-(n-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group;
      (xxii) Tetramethylcyclopropane-thiazole carboxamides: Any compound containing or structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2- (4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent, including the group Tetramethylcyclopropyl thiazoles, or any compound containing or structurally derived from 2,2,3,3-tetramethyl-N-(thiazol- 2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent. Tetramethylcyclopropane-thiazole carboxamides also include A-836,339, also known as:
        (I) [N(Z)]-N-[3-(2-methoxyethyl)-4,5-dimethyl-2(3H)-thiazolylidene]-2,2,3,3-tetramethyl-cyclopropanecarboxamide;
        (II) N-[3-(2-Methoxyethyl)-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-2,2,3,3-tetramethylcyclopropanecarboxamide: and
        (III) A-836339;
      (xxiii) Benzodihydropyrans: Any compound containing or structurally derived from benzodihydropyrans, by substitution on the benzyl ring by hydroxy, alkyl, haloalkyl, alkoxy, cycloalkyl, alkene, haloalkene, cycloalkane, or by substitution on the pyran ring by alkyl, cycloalkyl, cycloalkene, or cycloalkoxy group to any extent. Examples of this structural class include:
        (I) AM-855 (also known as (4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8,9, 10,11,12b-octahydronaphtho[3,2-c]isochromen-l 2-ol);
        (II) AM-905 (also known as (6aR,9R, l0aR)-3-[(E)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a, 7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol);
        (III) AM-906 (also known as (6aR,9R,10aR)-3-[(Z)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a, 7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol);
        (IV) AM-2389 (also known as (6aR,9R,10aR)-3-(l-hexylcyclobut-l-yl)-6a, 7,8,9,10,1Oa-hexahydro-6,6-dimethyl-6H-dibenzo[b,d)pyran-1,9 diol);and
        (V) JWH-057 (also known as (6aR,10aR)-3-(1,l-dimethylheptyl)-6a, 7, 10, 10a-tetrahydro-6,6,9-trimethyl-6H-Dibenzo[b,d]pyran); and
      (xxiv) Benzimidazole Ketone: Any compound containing or structurally derived from [IH-indazol-3-yl](l-naphthyl)methanone structure with or without substitution at either nitrogen atom of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, l-(N-methyl-2-pyrrolidinyl)methyl, l-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, l-amino-3-methyl-1-oxobutan-2-yl, l-amino-3, 3-dimethyl-1-oxobutan-2-yl, l-methoxy-3-methyl-1-oxobutan-2-yl, l-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Examples of this structural class include:
        (I) THJ-2201 (also known as [l-(5-Fluoropentyl)-lH-indazol-3-yl](l-naphthyl)methanone); and
        (II) THJ-018 (also known as l-naphthalenyl(l-pentyl-IH-indazol-3-yl)-methanone);
    (B) Unclassified Synthetic Cannabimimetic Agents:
      (i) AM-356, also known as:
        (I) AM356;
        (II) arachidonyl-1'-hydroxy-2'-propylamide;
        (III) N-(2-hydroxy-1R-methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide;
        (IV) (R)-(+)-Arachidonyl-1'-Hydroxy-2'-Propylamide;
        (V) Methanandamide; or
        (VI) R-1 Methanandamide;
      (ii) BAY38-7271 (also known as (-)-(R)-3-(2-Hydroxymethylindanyl -4-oxy) phenyl-4,4,4-trifluorobutyl-1-sulfonate);
      (iii) CP 50,556-1, also known as:
        (I) 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6, 6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate;
        (II) [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5- phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-; octahydrophenanthridin-1-yl] acetate;
        (III) [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; or
        (IV) "Levonantradol";
      (iv) HU-308 (also known as (91R,2R,5R)-2-[2,6-dimethoxy-4- (2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol);
      (v) HU-331 (also known as 3-hydroxy-2-[(1R,6R)-3-methyl-6- (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione);
      (vi) JTE-907 (also known as N-(benzol[1,3]dioxol-5-ylmethyl) –7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide);
      (vii) Mepirapim (also known as (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl) Methanone);
      (viii) URB597 (also known as [3-(3-carbamoylphenyl)phenyl] –N-Cyclohexylcarbamate);
      (ix) URB602, also known as:
        (I) [1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; or
        (II) cyclohexyl [1,1'-biphenyl]-3-ylcarbamate;
      (x) URB754 (also known as 6-methyl-2-[(4-methylphenyl)amino] -4H-3,1-benzoxazin-4-one); and
      (xi) URB937 (also known as 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl Cyclohexylcarbamate).
  (7) Synthetic opioids, which includes, unless specifically exempted, unless listed in another schedule, or unless approved by the Food and Drug Administration as a drug, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, their salts, isomers, homologues, analogues and salts of isomers, homologues, and analogues, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:
    (A) Classified Synthetic Opioids:
      (i) Fentanyls: Any compound, other than carbomethoxyfentanyls, containing or structurally derived from N-(1-(2-Phenylethyl)-4-piperidinyl)-N-phenylpropanamide, whether or not substituted on the methanone group with an alkyl, alkene, halo, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, cyanoalkyl, hydroxyalkyl, furanyl, or alkoxy, and whether or not substituted on either phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group. Examples of fentanyls include:
        (I) Fentanyl (also known as N-(1-(2-Phenylethyl)-4-piperidinyl)-N-phenylpropanamide);
        (II) Furanylfentanyl (also known as N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide);
        (III) Acetylfentanyl (also known as N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide);
        (IV) Acrylfentanyl (also known as N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]prop-2-enamide);
        (V) Parafluorofentanyl, also known as:
          (aa) 4-fluorofentanyl; or
          (bb) N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide;
        (VI) Butyryl fentanyl, also known as:
          (aa) Butyr fentanyl;
          (bb) NIH 10486; or
          (cc) N-phenyl-N-[l-(2-phenylethyl)-4-piperidinyl]-butanamide; and
        (VII) para-Fluorobutyryl fentanyl, also known as:
          (aa) 4-FPF;
          (bb) p-FBF;
          (cc) 4-Fluorobutyryl fentanyl;
          (dd) p-Fluorobutyryl fentanyl; or
          (ee) N-( 4-fluorophenyl)-N-[ l -(2-phenylethyl)-4-piperidinyl]-butanamide);
      (ii) Carbomethoxyfentanyls: Any compound containing or structurally derived from 4-((1-oxopropyl)-phenylamino )-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester, whether or not substituted on either phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group. Carbomethoxyfentanyls include:
        (I) Carfentanil, also known as:
          (aa) 4-Carbomethoxy Fentanyl;
          (bb) 4-carbomethoxy Fentanyl; or
          (cc) 4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylic acid, methyl ester;
        (II) Norcarfentanil (also known as: 4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester; and
        (III) N-methyl Norcarfentanil, also known as:
          (aa) N-methyl Carfentanil;
          (bb) N-methyl Norremifentanil;
          (cc) N-methyl Remifentanil; or
          (dd) 1-methyl-4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester; and
      (iii) Benzamides: Any compound containing or structurally derived from 3,4-Dichloro-N-[(1 R,2R)-2-(dimethylamino )cyclohexyl]-N-methylbenzamide, whether or not substituted on the phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group, and whether or not substituted with an alkyl or hydrogen on the nitrogen of the amide, and whether or not substituted on the nitrogen of the amide with an alkyl, cycloalkyl, tertiary amine, or combination thereof. Benzamides include:
        (I) U-47700 (also known as 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide); and
        (II) AH-7921 (also known as 3,4-dichloro-N-[[l-(dimethylamino)cyclohexyl]methyl]benzamide).
    (B) Unclassified Synthetic Opioids:
      (i) W-18 (also known as 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide);
      (ii) Sufentanil (also known as N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl-propanamide);
      (iii) Alfentanil (also known as N-[1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)-4-piperidinyl]-N-phenyl-propanamide);
      (iv) Remifentanil (also known as 4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic acid, methyl ester);
      (v) Lofentanil (also known as methyl (3R,4S)-3-methyl-1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate);
      (vi) Benzyl Carfentanil (also known as methyl 1-benzyl-4-(N-phenylpropionamido)piperidine-4-carboxylate); and
      (vii) N-methyl-Norcarfentanil (also known as 1-methyl-4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester).
D.C. Code § 48-853.09 — DC Code / Title 48 / Chapter 8G / § 48-853.09
§ 48-853.09. Unlawful disclosure of information and acts; disciplinary action authorized; penalties.
Status: in_force

(a) It shall be unlawful for any person having access to the confidential information in possession of the Program or any data or reports produced by the Program to disclose the confidential information except as provided in this chapter. Any person who discloses this confidential information in violation of the provisions of this chapter shall be guilty of a misdemeanor upon conviction.
(b) It shall be unlawful for any person who lawfully receives confidential information from the Program to redisclose or use the confidential information in any way other than the authorized purpose for which the request was made. Any person who discloses confidential information in violation of this chapter shall be guilty of a misdemeanor upon conviction.
(c) Nothing in this section shall prohibit a person who prescribes or dispenses a covered substance required to be reported to the program from redisclosing information obtained from the Program to another prescriber or dispenser who has prescribed or dispensed a covered substance to the same patient.
(d) Unauthorized use or disclosure of confidential information received from the Program shall also be grounds for disciplinary action by the relevant health occupations board.
D.C. Code § 48-803.04 — DC Code / Title 48 / Chapter 8 / § 48-803.04
§ 48-803.04. Dispensation of equivalent products by pharmacists — Recording and labeling required.
Status: in_force

When a drug is substituted under this subchapter , including the substitution of an interchangeable biological product, the pharmacist shall record on the prescription form the drug substituted by name and manufacturer, and retain the form for inspection by District officials. The pharmacist shall also label the prescription container with the name of the drug substituted, unless the prescribing physician writes “do not label,” or words of similar import, on the prescription, or, in communicating the prescription by telephone, orders that the container not be so labelled.
D.C. Code § 48-906.02 — DC Code / Title 48 / Chapter 9 / § 48-906.02
§ 48-906.02. Continuation of orders and rules.
Status: in_force

Any orders and rules issued under any law affected by this chapter and in effect on August 5, 1981, and not in conflict with it, continue in effect until modified, superseded, or repealed.
D.C. Code § 48-804.51 — DC Code / Title 48 / Chapter 8 / § 48-804.51
§ 48-804.51. Definitions.
Status: in_force

For the purposes of this chapter, the term:
(1) “Agent” means an individual who:
  (A) Is under the immediate and personal supervision of a prescriber or pharmacist and has written authorization, which shall be available for review upon request, to act on behalf of or at the direction of the prescriber or pharmacist when seeking or obtaining approval of a therapeutic interchange; or
  (B) If not under the immediate and personal supervision of a prescriber or pharmacist, holds a license to administer drugs, such as a nurse, physician’s assistant, or other pharmacist.
(1A) "Biological product" shall have the same meaning as provided in 42 U.S.C. § 262.
(2) “Endorsing prescriber” means a prescriber who has reviewed the therapeutic interchange list and has notified the Boards of Pharmacy and Medicine in writing that he or she has agreed to allow the therapeutic interchange.
(2A) "Interchangeable biological product" means a biological product that is:
  (A) Licensed and determined by the United States Food and Drug Administration to meet the standards for interchangeability under 42 U.S.C. § 262(k)(4); or
  (B) Determined to be biosimilar to and interchangeable with a reference biological product as stated in the latest edition of, or supplement to, the United States and Food and Drug administration's ("FDA") publication, "Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations" (known as the Purple Book).
(3) “Issue date” means the 1st day of the 4th full calendar month after April 7, 1977, and the day following the end of each year after the 1st such issue date.
(4) “Most commonly used prescription drugs” means the prescription drug products that were most frequently paid for by the Medicaid program operated by the District of Columbia government under a state plan filed in accordance with section 1902 of the Social Security Act (§ 1396a of Title 42, United States Code), in the 3 consecutive months ending 60 days before an issue date.
(5) “Person” means any individual, partnership, corporation, organization, or association.
(6) “Pharmacy” means a pharmacy that provides services to the public on an outpatient basis.
(7) “Prescriber” means a person who is licensed, registered, or otherwise authorized by the District to prescribe and administer prescription drugs for human use in the course of a professional practice.
(8) “Substitute drug product” means a drug product different than the one originally prescribed by a prescriber.
(9) “Therapeutic interchange” means the dispensing of chemically dissimilar but therapeutically equivalent drug products.
(10) “Therapeutic interchange list” means a list of therapeutically equivalent drug products.
(11) “Therapeutically equivalent drug product” means a drug product that is chemically dissimilar but produces essentially the same therapeutic outcome.
D.C. Code § 48-903.06 — DC Code / Title 48 / Chapter 9 / § 48-903.06
§ 48-903.06. Records and inventories of registrants.
Status: in_force

Persons registered to manufacture, distribute, or dispense controlled substances under this chapter shall keep records and maintain inventories in conformance with the record-keeping and inventory requirements of federal law, laws of the District of Columbia, and with any additional rules which the Mayor issues.
D.C. Code § 48-921.01 — DC Code / Title 48 / Chapter 9B / § 48-921.01
§ 48-921.01. Arrests, searches and seizures without warrant.
Status: in_force

(a) Repealed.
(b) Arrests without a warrant, and searches of the person and seizures pursuant thereto, may be made for a violation of subsection (a) of this section hereof by police officers, as in the case of a felony, upon probable cause that the person arrested is violating such subsection at the time of his arrest.
(c) No evidence discovered in the course of any such arrest, search, or seizure authorized by subsection (b) of this section hereof shall be admissible in any criminal proceeding against the person arrested unless at the time of such arrest he was violating the provisions of this section.
D.C. Code § 48-402.03 — DC Code / Title 48 / Chapter 4 / § 48-402.03
§ 48-402.03. Non-liability of the District.
Status: in_force

Nothing in this subchapter shall be construed to create governmental liability or a cause of action against the District related to the safety of food produced on land leased from the District pursuant to this section .
D.C. Code § 48-903.07 — DC Code / Title 48 / Chapter 9 / § 48-903.07
§ 48-903.07. Order forms.
Status: in_force

Controlled substances in Schedule I or II shall be distributed by a registrant to another registrant only pursuant to an order form. Compliance with the provisions of federal law respecting order forms shall be deemed compliance with this section.
D.C. Code § 48-303 — DC Code / Title 48 / Chapter 3 / § 48-303
§ 48-303. Date labels.
Status: in_force

(a) The Department of Health shall not:
  (1) Require a date label on food products that, based on current scientific evidence, do not pose an increased safety risk to consumers by a stated period; or
  (2) Limit the sale or donation of food products after their date label has passed, except for those food products that pose an increased safety risk to consumers when consumed after the date on the label.
(b) Within 120 days after February 22, 2019, the Department of Health shall issue rules to implement the provisions of this section.
(c) For the purposes of this section, the term "date label" refers to any date labeled on a food product, including those accompanied by the phrase "Best By", "Use By", "Sell By", "Best Before", "Expiration date", or any other descriptive phrase or date that is determined by the manufacturer to estimate when the food product might expire for use or be at its peak quality if it was handled and stored in a certain manner.
D.C. Code § 48-1001 — DC Code / Title 48 / Chapter 10 / § 48-1001
§ 48-1001. Definitions.
Status: in_force

(a) For the purposes of this chapter , the term:
  (1) "Chief of Police" means the Chief of the Metropolitan Police Department as the designated agent of the Mayor.
  (2) "Controlled Substances Act" means Chapter 9 of this title .
  (3) "Disperse" means to depart from the designated drug free zone and not to recongregate within the drug free zone with anyone from the group ordered to depart for the purpose of committing an offense under subchapter IV of Chapter 9 of this title for the duration of the zone.
  (4) "Drug free zone" means public space on public property in an area not to exceed a square of 1,000 feet on each side that is established pursuant to § 48-1002 .
  (5) "Illegal drug" means the same as the term "controlled substance" in § 48-901.02(4) .
  (6) "Known unlawful drug user, possessor, or seller" means a person who has, within the knowledge of the arresting officer, been convicted in any court of any violation involving the use, possession, or distribution of any of the substances referred to in subchapter IV of Chapter 9 of this title .
  (7) "Police Department" means the Metropolitan Police Department.
D.C. Code § 48-902.11 — DC Code / Title 48 / Chapter 9 / § 48-902.11
§ 48-902.11. Schedule V tests.
Status: in_force

The Mayor shall place a substance in Schedule V if the Mayor finds that:
(1) The substance has low potential for abuse relative to the controlled substances listed in Schedule IV;
(2) The substance has currently accepted medical use in treatment in the United States or the District of Columbia; and
(3) The substance has limited physical dependence or psychological dependence liability relative to the controlled substances listed in Schedule IV.
D.C. Code § 48-831.15 — DC Code / Title 48 / Chapter 8A / § 48-831.15
§ 48-831.15. Annual summary report.
Status: in_force

The Department shall submit a written report on the enrollment and financial status of AccessRx to the Council by the 2nd week of January each year.
D.C. Code § 48-801.05 — DC Code / Title 48 / Chapter 8 / § 48-801.05
§ 48-801.05. Services and drugs to be furnished at prices posted; exception.
Status: in_force

No pharmacy may fail to provide to any consumer the discounts and services stated on the poster, under the eligibility, price, and other terms there stated. Every sale of one of the 100 most commonly used prescription drugs, in a quantity and strength which requires the price of the drug to be posted, shall be at the posted price, unless a decrease in price is authorized by subchapter III of this chapter .
D.C. Code § 48-853.06 — DC Code / Title 48 / Chapter 8G / § 48-853.06
§ 48-853.06. Interoperability; information exchange with other prescription drug monitoring programs.
Status: in_force

(a) The Director may enter into written agreements with other prescription drug monitoring programs, or a third party, approved by the Director, that operates an interstate prescription drug monitoring exchange, for the purpose of interoperability and the mutual exchange of information among prescription drug monitoring programs, and describing the terms and conditions for the sharing of prescription information under this section.
(b) The Director may provide prescription monitoring information pursuant to such agreements, which shall only use the information for the purposes allowed by this chapter.
(c) The Director may request and receive prescription drug monitoring information from other states’ prescription drug monitoring programs and may use the information under the provisions of this chapter.
D.C. Code § 48-831.32 — DC Code / Title 48 / Chapter 8A / § 48-831.32
§ 48-831.32. Eligibility of the uninsured.
Status: in_force

To be eligible, an individual shall:
(1) Be a resident of the District;
(2) Have a household income that is not more than 350% of the federal poverty level; and
(3) Not be enrolled in any public or private medical insurance program.
D.C. Code § 48-608 — DC Code / Title 48 / Chapter 6 / § 48-608
§ 48-608. Promulgation and publication of regulations or standards to protect supply.
Status: repealed

Repealed.
D.C. Code § 48-302 — DC Code / Title 48 / Chapter 3 / § 48-302
§ 48-302. Authority of Mayor.
Status: in_force

Nothing in this chapter shall restrict the authority of the Mayor of the District of Columbia to inspect, condemn, denature, destroy, seize, or remove food for human consumption pursuant to § 22-2903 [repealed].
D.C. Code § 48-831.33 — DC Code / Title 48 / Chapter 8A / § 48-831.33
§ 48-831.33. Discounted prices for uninsured qualified residents.
Status: in_force

(a) Any participating retail pharmacy that sells prescription drugs covered by a rebate agreement pursuant to § 48-831.05 shall discount the retail price of those drugs sold to uninsured qualified residents.
(b) The Department shall establish discounted prices for drugs covered by a rebate agreement and shall promote the use of efficacious and reduced-cost drugs, taking into consideration reduced prices for state and federally capped drug programs, differential dispensing fees, administrative overhead, and incentive payments.
(c) Beginning January 1, 2005, a participating retail pharmacy shall offer the initial discounted price.
(d) Beginning no later than October 1, 2005, a participating retail pharmacy shall offer the secondary discounted price, if available.
D.C. Code § 48-843.01 — DC Code / Title 48 / Chapter 8D / § 48-843.01
§ 48-843.01. Short title.
Status: in_force

This chapter may be cited as the “Pharmaceutical Education Program Establishment Act of 2008”.
D.C. Code § 48-801.03 — DC Code / Title 48 / Chapter 8 / § 48-801.03
§ 48-801.03. Completion and display of posters.
Status: in_force

On and after each issue date, each pharmacy shall legibly post on the poster its current selling prices for the 100 most commonly used prescription drugs, the professional and convenience services it offers and the additional charges therefor, and the eligibility and terms of any discount it offers on prescription drugs. The completed poster shall be displayed prominently in the immediate vicinity of the prescription drug service area in such a manner as to be easily visible to consumers without having to obtain permission or assistance of an employee of the pharmacy.
D.C. Code § 48-904.08 — DC Code / Title 48 / Chapter 9 / § 48-904.08
§ 48-904.08. Second or subsequent offenses.
Status: in_force

(a) Any person convicted under this chapter of a second or subsequent offense may be imprisoned for a term up to twice the term otherwise authorized, fined an amount up to twice that otherwise authorized, or both.
(b) For purposes of this section, an offense is considered a second or subsequent offense if, prior to commission of the offense, the offender has at any time been convicted under this chapter or under any statute of the United States or of any state relating to a controlled substance.
(c) A person who is convicted of violating § 48-904.06 may be sentenced according to the provisions of § 48-904.06 or according to the provisions of this section, but not both.
D.C. Code § 48-831.17 — DC Code / Title 48 / Chapter 8A / § 48-831.17
§ 48-831.17. Rulemaking.
Status: in_force

The Mayor is authorized to issue any rules necessary to implement the provisions of this subchapter.
D.C. Code § 48-851.04 — DC Code / Title 48 / Chapter 8F / § 48-851.04
§ 48-851.04. Rules.
Status: in_force

(a) The Mayor, pursuant to subchapter I of Chapter 5 of Title 2 [ § 2-501 et seq.], shall issue rules to implement the provisions of § 48-851.03 . The rules shall specify safe, secure, and environmentally sound methods for health care facilities to dispose of used and unused pharmaceuticals.
(b) The Mayor, pursuant to subchapter I of Chapter 5 of Title 2 [ § 2-501 et seq.], may issue rules to implement the provisions of § 48-851.02 .
D.C. Code § 48-901.02 — DC Code / Title 48 / Chapter 9 / § 48-901.02
§ 48-901.02. Definitions.
Status: in_force

As used in this chapter, the term:
(a) (1) “Administer” means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by:
    (A) A practitioner (or, in the practitioner’s presence, by the practitioner’s authorized agent); or
    (B) The patient or research subject at the direction of and in the presence of the practitioner.
  (2) “Agent” means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. The term “agent” does not include a common or contract carrier, a public warehouseman, or an employee of the carrier or warehouseman, when acting in the usual and lawful course of the carrier’s or warehouseman’s business.
  (3) “Cannabis” means all parts of the plant genus Cannabis, including both marijuana and hashish defined as follows:
    (A) “Marijuana” includes the leaves, stems, flowers, and seeds of all species of the plant genus Cannabis, whether growing or not. The term “marijuana” does not include the resin extracted from any part of the plant, nor any compound, manufacture, salt, derivative, mixture, or preparation from the resin, including hashish and does not include the mature stalks of the plant, fiber produced from such stalks, oil, or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, fiber, oil, or cake, or the sterilized seed of the plant which is incapable of germination.
    (B) “Hashish” includes the resin extracted from any part of the plant genus Cannabis, and every compound, manufacture, salt, derivative, mixture, or preparation from such resin.
  (3A) “Contraband” means an item the mere possession of which is unlawful under District or federal law.
  (4) “Controlled substance” means a drug, substance, or immediate precursor, as set forth in Schedules I through V of subchapter II of this chapter .
  (5) “Counterfeit substance” means a controlled substance which, or the container or labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, number or device, or any likeness thereof, of a manufacturer, distributor, or dispenser other than the person who in fact manufactured, distributed, or dispensed the substance.
  (6) “D.E.A.” means the Drug Enforcement Administration of the United States Department of Justice or its successor agency.
  (7) “Dispense” means to distribute a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the prescribing, administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery.
  (8) “Dispenser” means a practitioner who dispenses.
  (9) “Distribute” means the actual, constructive, or attempted transfer from one person to another other than by administering or dispensing of a controlled substance, whether or not there is an agency relationship.
  (10) “Distributor” means a person who distributes.
  (11) “Drug” means: (A) substances recognized as drugs in the official United States Pharmacopoeia, the official Homeopathic Pharmacopoeia of the United States, or the official National Formulary, or any supplement to any of them; (B) active substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or animals; (C) substances (other than food) intended to affect the structure or any function of the body of man or animals; and (D) substances intended for use as a component of any article specified in clause (A), (B), or (C) of this paragraph. The term “drug” does not include devices or their components, parts, or accessories.
  (12) “Immediate precursor” means a substance which the Mayor has found to be, and by rule designates as being, the principal compound commonly used or produced primarily for use, and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.
  (13) “Manufacture” means the production, preparation, propagation, compounding, conversion or processing of a controlled substance, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container. The term “manufacture” does not include the preparation or compounding of a controlled substance by an individual for his or her own use or the preparation, compounding, packaging, or labeling of a controlled substance:
    (A) By a practitioner as an incident to administering or dispensing a controlled substance in the course of the practitioner’s professional practice; or
    (B) By a practitioner, or by his or her authorized agent under supervision, for the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale.
  (14) “Mayor” means the Mayor as provided for in § 1-204.21 , or the Mayor’s designated agent.
  (15) “Narcotic drug” means any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
    (A) Opium, its phenanthrene alkaloids, and their derivatives (except isoquiniline alkaloids of opium);
    (B) Any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent to or identical with any of the substances referred to in subparagraph (A) of this paragraph;
    (C) Opium poppy and poppy straw;
    (D) Cocaine, its salts, optical and geometric isomers, and salts of isomers;
    (E) Ecgonine, its derivatives, their salts, isomers, and salts of isomers; and
    (F) Any compound, mixture, or preparation that contains any of the substances referred to in this paragraph.
  (16) “Opiate” means any drug or other substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability and includes its racemic and levorotatory forms. The term “opiate” does not include, unless specifically designated as controlled under § 48-902.01 , the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan).
  (17) “Opium poppy” means the plant of the species Papaver somniferum L., except its seeds.
  (18) “Person” means an individual, corporation, government, or governmental subdivision or agency, business trust, estate, trust, partnership, or association, or unincorporated business, or any other legal entity.
  (19) “Poppy straw” means all parts, except the seeds, of the opium poppy, after mowing.
  (20) “Practitioner” means:
    (A) A physician, dentist, advanced practice registered nurse, veterinarian, scientific investigator, or other person licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, or to administer a controlled substance in the course of professional practice or research in the District of Columbia; or
    (B) A pharmacy, hospital, or other institution licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, or to administer a controlled substance in the course of its professional practice or research in the District of Columbia.
  (21) “Production” includes the manufacture, planting, cultivation, growing, or harvesting of a controlled substance.
  (22) “State” when applied to a part of the United States, includes any state, the District of Columbia, commonwealth, territory, insular possession thereof, and any area subject to the legal authority of the United States government.
  (23) “Ultimate user” means a person who lawfully possesses a controlled substance for that person’s own use or for the use of a member of that person’s household or for administering to an animal owned by him or her or by a member of that person’s household.
  (24) “Addict” means any individual who habitually uses any narcotic drug or abusive drug so as to endanger the public morals, health, safety, or welfare, or who is or has been so far addicted to the use of such narcotic drug or abusive drug as to have lost the power of self-control with reference to his addiction.
  (25) “Retail value” means the value in the market in which the substance was being distributed, manufactured or possessed, or the amount which the person possessing such controlled substance reasonably could have expected to receive upon the sale of the controlled substance at the time and place where the controlled substance was distributed, manufactured or possessed.
  (26) “Abusive drug” means any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:
    (A) Phencyclidine or a phencyclidine immediate precursor;
    (B) Methamphetamine, its salts, isomers, and salts of its isomers; and
    (C) Phenmetrazine and its salts.
  (27) “Isomer” means the optical isomer, except as used in §§ 48-902.04(3) , (5) , and (6) and 48-902.06(1)(D) . As used in § 48-902.04(3) , (5) , and (6) , “isomer” means any optical, positional, or geometric isomer. As used in § 48-902.06(1)(D) , “isomer” means any optical or geometric isomer.
  (28) “Real property” means any right, title, or interest in any tract of land, or any appurtenance or improvement on a tract of land.
  (29) “Playground” means any facility intended for recreation, open to the public, and with any portion of the facility that contains one or more separate apparatus intended for the recreation of children, including, but not limited to, sliding boards, swingsets, and teeterboards.
  (30) “Video arcade” means any facility legally accessible to persons under 18 years of age, intended primarily for the use of pinball and video machines for amusement, and which contains a minimum of 10 pinball or video machines.
  (31) “Youth center” means any recreational facility or gymnasium, including any parking lot appurtenant thereto, intended primarily for use by persons under 18 years of age, which regularly provides athletic, civic, or cultural activities.
D.C. Code § 48-904.01 — DC Code / Title 48 / Chapter 9 / § 48-904.01
§ 48-904.01. Prohibited acts A; penalties.
Status: in_force

(a) (1) Except as authorized by this chapter or Chapter 16B of Title 7 [ § 7-1671.01 et seq.], it is unlawful for any person knowingly or intentionally to manufacture, distribute, or possess, with intent to manufacture or distribute, a controlled substance. Notwithstanding any provision of this chapter to the contrary, it shall be lawful, and shall not be an offense under District of Columbia law, for any person 21 years of age or older to:
    (A) Possess, use, purchase, or transport marijuana weighing 2 ounces or less;
    (B) Transfer to another person 21 years of age or older, without remuneration, marijuana weighing one ounce or less;
    (C) Possess, grow, harvest, or process, within the interior of a house or rental unit that constitutes such person’s principal residence, no more than 6 cannabis plants, with 3 or fewer being mature, flowering plants; provided, that all persons residing within a single house or single rental unit may not possess, grow, harvest, or process, in the aggregate, more than 12 cannabis plants, with 6 or fewer being mature, flowering plants;
    (D) Possess within such house or rental unit the marijuana produced by such plants; provided that, nothing in this subsection shall make it lawful to sell, offer for sale, or make available for sale any marijuana or cannabis plants.
  (1A) (A) The terms “controlled substance” and “controlled substances,” as used in the District of Columbia Official Code, shall not include:
      (i) Marijuana that is or was in the personal possession of a person 21 years of age or older at any specific time if the total amount of marijuana that is or was in the possession of that person at that time weighs or weighed 2 ounces or less;
      (ii) Cannabis plants that are or were grown, possessed, harvested, or processed by a person 21 years of age or older within the interior of a house or rental unit that constitutes or at the time constituted, such person’s principal residence, if such person at that time was growing no more than 6 cannabis plants with 3 or fewer being mature flowering plants and if all persons residing within that single house or single rental unit at that time did not possess, grow, harvest, or process, in the aggregate, more than 12 cannabis plants, with 6 or fewer being mature, flowering plants; or
      (iii) The marijuana produced by the plants which were grown, possessed, harvested, or processed by a person who was, pursuant to sub-subparagraph (ii) of this subparagraph, permitted to grow, possess, harvest, and process such plants, if such marijuana is or was in the personal possession of that person who is growing or grew such plants, within the house or rental unit in which the plants are or were grown.
    (B) Notwithstanding the provisions of this paragraph, the terms “controlled substance” and “controlled substances,” as used in the District of Columbia Official Code, shall include any marijuana or cannabis plant sold or offered for sale or made available for sale.
  (1B) Notwithstanding any other provision of the District of Columbia Official Code, no District government agency or office shall limit or refuse to provide any facility service, program, or benefit to any person based upon or by reason of conduct that is made lawful by this subsection.
  (1C) Nothing in this subsection shall be construed to require any District government agency or office, or any employer, to permit or accommodate the use, consumption, possession, transfer, display, transportation, sale, or growing of marijuana in the workplace or to affect the ability of any such agency, office, or employer to establish and enforce policies restricting the use of marijuana by employees.
  (1D) Nothing in this subsection shall be construed to permit driving under the influence of marijuana or driving while impaired by use or ingestion of marijuana or to modify or affect the construction or application of any provision of the District of Columbia Official Code related to driving under the influence of marijuana or driving while impaired by marijuana.
  (1E) Nothing in this subsection shall be construed to prohibit any person, business, corporation, organization, or other entity, or District government agency or office, who or which occupies, owns, or controls any real property, from prohibiting or regulating the possession, consumption, use, display, transfer, distribution, sale, transportation, or growing of marijuana on or in that property.
  (1F) Nothing in this subsection shall be construed to make unlawful any conduct permitted by Chapter 16B of Title 7 [ § 7-1671.01 et seq.].
  (2) Any person who violates this subsection with respect to:
    (A) A controlled substance classified in Schedule I or II that is a narcotic or abusive drug shall be imprisoned for not more than 30 years or fined not more than the amount set forth in § 22-3571.01 , or both;
    (B) Any other controlled substance classified in Schedule I, II, or III, except for a narcotic or abusive drug, is guilty of a crime and upon conviction may be imprisoned for not more than 5 years, fined not more than the amount set forth in § 22-3571.01 , or both; except that upon conviction of manufacturing, distributing or possessing with intent to distribute ½ pound or less of marijuana, a person who has not previously been convicted of manufacturing, distributing or possessing with intent to distribute a controlled substance or attempting to manufacture, distribute, or possess with intent to distribute a controlled substance may be imprisoned for not more than 180 days or fined not more than the amount set forth in § 22-3571.01 or both;
    (C) A substance classified in Schedule IV, is guilty of a crime and upon conviction may be imprisoned for not more than 3 years, fined not more than the amount set forth in § 22-3571.01 , or both; or
    (D) A substance classified in Schedule V, is guilty of a crime and upon conviction may be imprisoned for not more than one year, fined not more than the amount set forth in § 22-3571.01 , or both.
(b) (1) Except as authorized by this chapter, it is unlawful for any person to create, distribute, or possess with intent to distribute a counterfeit substance.
  (2) Any person who violates this subsection with respect to:
    (A) A counterfeit substance classified in Schedule I or II that is a narcotic or abusive drug shall be imprisoned for not more than 30 years or fined not more than the amount set forth in § 22-3571.01 , or both;
    (B) Any other counterfeit substance classified in Schedule I, II, or III, except for a narcotic or abusive drug, is guilty of a crime and upon conviction may be imprisoned for not more than 5 years, fined not more than the amount set forth in § 22-3571.01 , or both;
    (C) A counterfeit substance classified in Schedule IV, is guilty of a crime and upon conviction may be imprisoned for not more than 3 years, fined not more than the amount set forth in § 22-3571.01 , or both; or
    (D) A counterfeit substance classified in Schedule V, is guilty of a crime and upon conviction may be imprisoned for not more than 1 year, fined not more than the amount set forth in § 22-3571.01 , or both.
(c) Repealed.
(d) (1) It is unlawful for any person knowingly or intentionally to possess a controlled substance unless the substance was obtained directly from, or pursuant to, a valid prescription or order of a practitioner while acting in the course of his or her professional practice, or except as otherwise authorized by this chapter or Chapter 16B of Title 7 [ § 7-1671.01 et seq.], and provided in § 48-1201 . Except as provided in paragraph (2) of this subsection, any person who violates this subsection is guilty of a misdemeanor and upon conviction may be imprisoned for not more than 180 days, fined not more than the amount set forth in § 22-3571.01 , or both.
  (2) Any person who violates this subsection by knowingly or intentionally possessing the abusive drug phencyclidine in liquid form is guilty of a felony and, upon conviction, may be imprisoned for not more than 3 years, fined not more than the amount set forth in § 22-3571.01 , or both.
(e) (1) If any person who has not previously been convicted of violating any provision of this chapter, or any other law of the United States or any state relating to narcotic or abusive drugs or depressant or stimulant substances is found guilty of a violation of subsection (d) of this section and has not previously been discharged and had the proceedings dismissed pursuant to this subsection, the court may, without entering a judgment of guilty and with the consent of such person, defer further proceedings and place him or her on probation upon such reasonable conditions as it may require and for such period, not to exceed one year, as the court may prescribe. Upon violation of a condition of the probation, the court may enter an adjudication of guilt and proceed as otherwise provided. The court may, in its discretion, dismiss the proceedings against such person and discharge him or her from probation before the expiration of the maximum period prescribed for such person’s probation. If during the period of probation such person does not violate any of the conditions of the probation, then upon expiration of such period the court shall discharge such person and dismiss the proceedings against him or her. Discharge and dismissal under this subsection shall be without court adjudication of guilt, but a nonpublic record thereof shall be retained solely for the purpose of use by the courts in determining whether or not, in subsequent proceedings, such person qualifies under this subsection. Such discharge or dismissal shall not be deemed a conviction for purposes of disqualifications or disabilities imposed by law upon conviction of a crime (including the penalties prescribed under § 48-904.08 for second or subsequent convictions) or for any other purpose.
  (2) Upon the dismissal of such person and discharge of the proceedings against him under paragraph (1) of this subsection, such person may apply to the court for an order to expunge from all official records (other than the nonpublic records to be retained under paragraph (1) of this subsection) all recordation relating to his or her arrest, indictment or information, trial, finding of guilty, and dismissal and discharge pursuant to this subsection. If the court determines, after hearing, that such person was dismissed and the proceedings against him or her discharged, it shall enter such order. The effect of such order shall be to restore such person, in the contemplation of this law, to the status he or she occupied before such arrest or indictment or information. No person as to whom such order has been entered shall be held thereafter under any provision of any law to be guilty of perjury or otherwise giving a false statement by reason of failure to recite or acknowledge such arrest, or indictment, or trial in response to any inquiry made of him or her for any purpose.
  (3) A person who was discharged from probation and whose case was dismissed pursuant to paragraph (1) of this subsection shall be entitled to a copy of the nonpublic record retained under paragraph (1) of this subsection but only to the extent that such record would have been available to the person before an order of expungement was entered pursuant to paragraph (2) of this subsection. A request for a copy of the nonpublic record may be made ex parte and under seal by the person or by an authorized representative of the person.
(f) The prosecutor may charge any person who violates the provisions of subsection (a) or (b) of this section relating to the distribution of or possession with intent to distribute a controlled or counterfeit substance with a violation of subsection (d) of this section if the interests of justice so dictate.
(g) For the purposes of this section, “offense” means a prior conviction for a violation of this section or a felony that relates to narcotic or abusive drugs, marijuana, or depressant or stimulant drugs, that is rendered by a court of competent jurisdiction in the United States.
D.C. Code § 48-105 — DC Code / Title 48 / Chapter 1 / § 48-105
§ 48-105. Complaints to be investigated.
Status: in_force

It shall be the duty of the Mayor to investigate a complaint for a violation of any of the provisions of this chapter on the information of any person who lays before him satisfactory evidence by which to substantiate such complaints.
D.C. Code § 48-904.07a — DC Code / Title 48 / Chapter 9 / § 48-904.07a
§ 48-904.07a. Drug free zones.
Status: in_force

(a) All areas within 1000 feet of an appropriately identified public or private day care center, elementary school, vocational school, secondary school, junior college, college, or university, or any public swimming pool, playground, video arcade, youth center, or public library, or in and around public housing, as defined in section 3(1) of the United States Housing Act of 1937, approved August 22, 1974 (88 Stat. 654; 42 U.S.C. § 1437a(b)), the development or administration of which is assisted by Department of Housing and Urban Development, or in or around housing that is owned, operated, or financially assisted by the District of Columbia Housing Authority, or an event sponsored by any of the above entities shall be declared a drug free zone. For the purposes of this subsection, the term “appropriately identified” means that there is a sign that identifies the building or area as a drug free zone.
(b) Any person who violates § 48-904.01(a) by distributing or possessing with the intent to distribute a controlled substance which is listed in Schedule I, II, III, IV, or V within a drug free zone shall be punished by a fine up to twice that otherwise authorized by this chapter to be imposed, by a term of imprisonment up to twice that otherwise imposed, or both.
D.C. Code § 48-831.12 — DC Code / Title 48 / Chapter 8A / § 48-831.12
§ 48-831.12. Method of prescribing or ordering drugs.
Status: in_force

The method of prescribing or ordering drugs may include, but is not limited to, the use of standard or larger prescription refill sizes in order to minimize operational costs and maximize economy. Unless the prescribing physician indicates otherwise, the use of the lowest cost generic or chemically equivalent drugs is required; provided, that these drugs are of the same quality and have the same mode of delivery as is provided to the general public, consistent with good pharmaceutical practice.
D.C. Code § 48-852.01 — DC Code / Title 48 / Chapter 8F / § 48-852.01
§ 48-852.01. Definitions.
Status: repealed

Repealed.
D.C. Code § 48-1121 — DC Code / Title 48 / Chapter 11 / § 48-1121
§ 48-1121. Distribution of needle or syringe near schools prohibited.
Status: in_force

(a) Repealed.
(b) The Public Housing Police of the District of Columbia Housing Authority shall prepare a monthly report on activity involving illegal drugs at or near any public housing site where a needle exchange program is conducted, and shall submit such reports to the Executive Director of the District of Columbia Housing Authority, who shall submit them to the Committees on Appropriations of the House of Representatives and Senate. The Executive Director shall ascertain any concerns of the residents of any public housing site about any needle exchange program conducted on or near the site, and this information shall be included in these reports.  The District of Columbia Government shall take appropriate action to require relocation of any such program if so recommended by the police or by a significant number of residents of such site.
D.C. Code § 48-107 — DC Code / Title 48 / Chapter 1 / § 48-107
§ 48-107. Portion of sample analyzed to be sealed and retained.
Status: in_force

In all cases where any drug or article of food shall be taken as a sample to be examined and analyzed, the person making the analysis shall reserve a portion of the sample, which shall be sealed, for a period of 30 days from the time of taking such sample, and in case of a complaint the reserved portion alleged to be adulterated shall, upon application, be delivered to the defendant or his attorney.
D.C. Code § 48-853.02 — DC Code / Title 48 / Chapter 8G / § 48-853.02
§ 48-853.02. Program establishment; Director’s authority.
Status: in_force

(a) There is established the Prescription Drug Monitoring Program within the Department. The Program shall:
  (1) Establish, maintain, and administer an electronic system to monitor the dispensing of covered substances;
  (2) Provide dispensers with a basic file layout to enable electronic transmission of the information required under this chapter; and
  (3) Establish and maintain a process for verifying the credentials of and authorizing the use of prescription information by those individuals and agencies listed in § 48-853.05(b) and (c).
(b) The Director may contract with another District agency or a private vendor as may be necessary for the implementation and maintenance of the Program. Any such contractor shall be bound to comply with the provisions regarding confidentiality of data in this chapter and shall be subject to the penalties specified in this chapter.
(c) The Director shall also establish a multi-discipline advisory committee, which shall function under the Department to assist in the implementation and evaluation of the Program.
D.C. Code § 48-855.01 — DC Code / Title 48 / Chapter 8H / § 48-855.01
§ 48-855.01. Definitions.
Status: in_force

For the purposes of this chapter , the term:
(1) "Class of drugs" means a group of medications having similar actions designed to treat a particular disease process.
(2) "Coinsurance" means a cost-sharing amount set as a percentage of the total cost of a drug.
(3) "Copayment" means a cost-sharing amount set as a dollar value.
(3A) "Diabetes device" means a legend device or non-legend device used to cure, diagnose, mitigate, prevent or treat diabetes or low blood sugar.  The term includes a blood glucose test strip, glucometer, continuous glucometer, lancet, lancing device, or insulin syringe.
(3B) "Diabetic ketoacidosis device" means a device that is a legend or non-legend device and used to screen for or prevent diabetic ketoacidosis. The term includes diabetic ketoacidosis devices prescribed and dispensed once during a policy year.
(3C) "Generic drug" means a chemically equivalent copy of a brand-name drug with an expired patent.
(4) (A) "Health benefit plan" means a policy, contract, certificate, or agreement offered or issued by a health carrier to provide, deliver, arrange for, pay for, or reimburse any of the costs of health care services.
  (B) The term "health benefit plan" does not include:
    (i) Coverage only for accident or disability income insurance, or any combination thereof;
    (ii) Liability insurance, including general liability insurance and automobile liability insurance;
    (iii) Coverage issued as a supplement to liability insurance;
    (iv) Workers' compensation or similar insurance;
    (v) Automobile medical payment insurance;
    (vi) Credit-only insurance;
    (vii) Coverage for on-site medical clinics; or
    (viii) Other similar insurance coverage specified in federal regulations issued pursuant to the Health Insurance Portability and Accountability Act of 1996, approved August 21, 1996 (110 Stat. 1936; scattered sections of the United States Code) ("HIPAA"), under which benefits for health care services are secondary or incidental to other insurance benefits.
  (C) The term "health benefit plan" does not include the following benefits if they are provided under a separate policy, certificate of insurance, or contract of insurance, or are otherwise not an integral part of the plan:
    (i) Limited scope dental or vision benefits;
    (ii) Benefits for long-term care, nursing-home care, home-health care, community-based care, or any combination thereof; or
    (iii) Other similar, limited benefits specified in federal regulations issued pursuant to HIPAA.
  (D) The term "health benefit plan" does not include the following benefits if the benefits are provided under a separate policy, certificate of insurance, or contract of insurance, and there is no coordination between the provision of the benefits and any exclusion of benefits under any group health plan maintained by the same health insurer, and the benefits are paid with respect to an event without regard to whether benefits are provided with respect to such an event under any group health plan maintained by the same health insurer:
    (i) Coverage only for a specified disease or illness; or
    (ii) Hospital indemnity or other fixed indemnity insurance.
  (E) The term "health benefit plan" does not include the following if offered as a separate policy, certificate of insurance, or contract of insurance:
    (i) A Medicare supplemental policy as defined in section 1882(g)(1) of the Social Security Act, approved June 9, 1980 (94 Stat. 476; 42 U.S.C. § 1395ss(g)(1));
    (ii) Coverage supplemental to the coverage provided under An Act To amend titles 10, 14, and 32, United States Code, to codify recent military law, and to improve the Code, approved September 2, 1958 (72 Stat. 1437; 10 U.S.C. § 1071 et seq .); or
    (iii) Similar supplemental coverage provided under a group health plan.
(5) "Health insurer" means any person that provides one or more health benefit plans or insurance in the District of Columbia, including an insurer, a hospital and medical services corporation, a fraternal benefit society, a health maintenance organization, a multiple employer welfare arrangement, or any other person providing a plan of health insurance subject to the authority of the Commissioner of the Department of Insurance, Securities and Banking.
(5A) "Interchangeable biological product" means a biological product that is licensed and determined by the Food and Drug Administration to meet the standards for interchangeability under 42 U.S.C. § 262(k)(4) or determined to be biosimilar to and interchangeable with a reference biological product as stated in the Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations, also known as the Purple Books.
(6) "Member" means an individual who is enrolled in a health benefit plan.
(7) "Member representative" means a:
  (A) Person acting on behalf of a member with the member's consent;
  (B) Person authorized by law to provide substituted consent for a member;
  (C) Family member of the member;
  (D) Member's treating health care professional when the member is unable to provide consent; or
  (E) In the case of a request regarding an emergency or urgent medical condition, a health-care professional with knowledge of the member's medical condition.
(8) "Non-preferred drug" means a specialty drug formulary classification for certain specialty drugs that are subject to limits on eligibility for coverage or to higher cost-sharing amounts than preferred specialty drugs.
(9) "Preferred drug" means a specialty drug formulary classification for certain specialty drugs that are not subject to limits on eligibility for coverage or to higher cost-sharing amounts than a non-preferred drug.
(9A) "Prescription insulin drug" means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(10) "Specialty drug" means a prescription drug that:
  (A) Is prescribed for a person with:
    (i) A physical, behavioral, or developmental condition that may have no known cure, is progressive, or can be debilitating or fatal if left untreated or undertreated, such as multiple sclerosis, hepatitis C, or rheumatoid arthritis; or
    (ii) A disease or condition that affects fewer than 200,000 persons in the United States or approximately one in 1,500 persons worldwide, such as cystic fibrosis, hemophilia, or multiple myeloma;
  (B) Has a total monthly prescription cost of $600 or more; and
  (C) Has one or more of the following characteristics:
    (i) Is an oral, injectable, or infusible drug product or a drug product that is delivered topically, through inhalation, implantation, or transmucosally;
    (ii) Requires unique storage or shipment, such as refrigeration; or
    (iii) Requires patient education and support beyond traditional dispensing activities.
(11) "Specialty tier" means a tier of cost sharing designed for select specialty drugs that imposes a cost-sharing obligation that is based on a coinsurance or copayment and exceeds that amount for non-specialty drugs.
(12) "Step therapy" means a protocol established by a health insurer that requires a prescription drug or sequence of prescription drugs to be used by an insured or an enrollee before a prescription drug ordered by a prescriber for the insured or the enrollee is covered.
(13) "Tiered formulary" means a formulary that provides coverage for prescription drugs as part of a health benefit plan for which cost-sharing, deductibles, or coinsurance is determined by category or tier of prescription drugs, and that includes at least 2 different tiers.
D.C. Code § 48-1101 — DC Code / Title 48 / Chapter 11 / § 48-1101
§ 48-1101. Definitions.
Status: in_force

For purposes of this subchapter, the term:
(1) Blunt wrap” means any product that is manufactured for encasing, wrapping, or rolling materials of any kind for purposes of smoking, if such product is designed to be filled by the consumer and is:
  (A) Made wholly or in part of tobacco; or
  (B) Made of paper or any other material that does not contain tobacco, and is:
    (i) Intended, when filled by the consumer, to produce a finished wrap that measures more than 120 millimeters on its longest side; or
    (ii) Sold as a pre-rolled hollow cone, the circumference of which is not equal at both ends.
(1A) “Controlled substance” has the same meaning as that provided in § 48-901.02(4) .
(2) “Court” means the Superior Court of the District of Columbia and the District of Columbia Court of Appeals.
(3) “Drug paraphernalia” means:
  (A) Kits or other objects used, intended for use, or designed for use in planting, propagating, cultivating, growing, or harvesting of any species of plant which is a controlled substance or from which a controlled substance can be derived;
  (B) Kits or other objects used, intended for use, or designed for use in manufacturing, compounding, converting, producing, processing, or preparing a controlled substance;
  (C) Isomerization devices or other objects used, intended for use, or designed for use in increasing the potency of any species of plant which is a controlled substance;
  (D) Testing equipment or other objects used, intended for use, or designed for use in identifying or analyzing the strength, effectiveness, or purity of a controlled substance;
  (E) Scales and balances or other objects used, intended for use, or designed for use in weighing or measuring a controlled substance;
  (F) Diluents and adulterants, including, but not limited to: quinine, hydrochloride, mannitol, mannite, dextrose, and lactose, used, intended for use, or designed for use in cutting a controlled substance;
  (G) Separation gins and sifters or other objects used, intended for use, or designed for use in removing twigs and seeds from, or in otherwise cleaning or refining, Cannabis or any other controlled substance;
  (H) Blenders, bowls, containers, spoons, and other mixing devices used, intended for use, or designed for use in compounding a controlled substance;
  (I) Capsules, balloons, envelopes, glassy plastic bags, or zip-lock bags that measure 1 inch by 1 inch or less, and other containers used, intended for use, or designed for use in packaging small quantities of a controlled substance;
  (J) Containers and other objects used, intended for use, or designed for use in storing or concealing a controlled substance;
  (K) Hypodermic syringes, needles, and other objects used, intended for use, or designed for use in parenterally injecting a controlled substance into the human body; and
  (L) Objects used, intended for use, or designed for use in ingesting, inhaling, or otherwise introducing Cannabis, cocaine, hashish, hashish oil, or any other controlled substance into the human body, including, but not limited to:
    (i) Metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes with or without screens, permanent screens, hashish heads, or punctured metal bowls;
    (ii) Water pipes;
    (iii) Carburetion tubes and devices;
    (iv) Smoking and carburetion masks;
    (v) Roach clips;
    (vi) Miniature spoons with level capacities of one-tenth cubic centimeter or less;
    (vii) Chamber pipes;
    (viii) Carburetor pipes;
    (ix) Electric pipes;
    (x) Air-driven pipes;
    (xi) Bongs;
    (xii) Ice pipes or chillers;
    (xiii) Wired cigarette papers;
    (xiv) Cocaine freebase kits; or
    (xv) Cigarette rolling paper or cigar wrappers sold at a commercial retail or wholesale establishment, which does not derive at least 25% of its total annual revenue from the sale of tobacco products and which does not sell loose tobacco intended to be rolled into cigarettes and cigars.
  The term “drug paraphernalia” shall not include any article that is 50 years of age or older.
(4) "Personal use" means use or possession in circumstances where there is insufficient evidence of intent to distribute or manufacture a controlled substance.
D.C. Code § 48-654 — DC Code / Title 48 / Chapter 6A / § 48-654
§ 48-654. Limitation on fees.
Status: in_force

(a) Notwithstanding any other local law, resolution, rule, or regulation relating to limitations on the fees charged to restaurants by third-party meal delivery platforms, no third-party meal delivery platform may charge a restaurant a fee, commission, or charge per online order that totals more than 15% of the purchase price of the online order or totals more than 5% of the purchase price per online order where the platform does not deliver the order.
(b) The fee limits in subsection (a) of this section shall not apply to a third-party meal delivery platform that:
  (1) Offers all restaurants the option to obtain core delivery service for a total fee, commission, or charge that is no more than 15% of the purchase price of the online order, without requiring the purchase of additional services; and
  (2) Within 30 days of March 10, 2023, notifies all restaurants that have an existing agreement with the third-party meal delivery platform of the option described in paragraph (1) of this subsection.
D.C. Code § 48-902.08 — DC Code / Title 48 / Chapter 9 / § 48-902.08
§ 48-902.08. Schedule III enumerated.
Status: in_force

(a) The controlled substances listed in this section are included in Schedule III, unless and until removed therefrom pursuant to § 48-902.01 :
  (1) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
    (A) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;
    (B) Benzphetamine;
    (C) Chlorphentermine;
    (D) Chlortermine;
    (E) Mazindol; and
    (F) Phendimetrazine;
  (2) Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:
    (A) Any compound, mixture, or preparation containing:
      (i) Amobarbital;
      (ii) Secobarbital; or
      (iii) Pentobarbital; or any salt thereof and 1 or more other active medicinal ingredients which are not listed in any schedule;
    (B) Any suppository dosage form containing:
      (i) Amobarbital;
      (ii) Secobarbital;
      (iii) Pentobarbital; or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;
    (C) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid:
      (i) Chlorhexadol;
      (ii) Rescheduled to Schedule II;
      (iii) Lysergic acid;
      (iv) Lysergic acid amide;
      (v) Methyprylon;
      (vi) Sulfondiethylmethane;
      (vii) Sulfonethylmethane;
      (viii) Sulfonmethane;
      (ix) Tiletamine & Zolazepam Combination Product; and
      (x) Vinbarbital;
  (3) Nalorphine;
  (4) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:
    (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
    (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;
    (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a 4-fold or greater quantity of an isoquinoline alkaloid of opium;
    (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;
    (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;
    (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with 1 or more ingredients in recognized therapeutic amounts;
    (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts; and
    (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;
  (5) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, drug, or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progesterons, and corticorsteroids) that promotes muscle growth and includes:
    (A) Boldenone;
    (B) Chlortestosterone (4-chlortestosterone);
    (C) Clostebol;
    (D) Dehydrochlormethyltestosterone;
    (E) Dihydrotestosterone (4-dihydrotestosterone);
    (F) Drostanolone;
    (G) Ethylestrenol;
    (H) Fluoxymestorone;
    (I) Formebulone (formebolone);
    (J) Mesterolone;
    (K) Methandienone;
    (L) Methandranone;
    (M) Methandriol;
    (N) Methandrostenolone;
    (O) Methenolone;
    (P) Methyltestosterone;
    (Q) Mibolerone;
    (R) Nandrolone;
    (S) Norethandrolone;
    (T) Oxandrolone;
    (U) Oxymesterone;
    (V) Oxymetholone;
    (W) Stanolone;
    (X) Stanozolol;
    (Y) Testolactone;
    (Z) Testosterone;
    (AA) Trenbolone; and
    (BB) Any salt, ester or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Except such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by Secretary of Health and Human Services for such administration. If any person prescribes, dispenses or distributes such steroid for human use such person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this paragraph; and
  (6) Cannabis.
  (7) Repealed.
(b) The Mayor may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in paragraphs (1) and (2) of subsection (a) of this section from the application of all or any part of this chapter if the compound, mixture, or preparation contains 1 or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.
D.C. Code § 48-401 — DC Code / Title 48 / Chapter 4 / § 48-401
§ 48-401. Definitions.
Status: in_force

(a) For the purposes of this subchapter , the term:
  (1) "Department" means the Department of Energy and Environment".
  (2) "Horticultural techniques" means the scientific, artistic, and technological methods used to cultivate and manage an agricultural space, such as growing from the ground, hydroponics, container farming, vertical farming, or growing in greenhouses or raised beds.
  (3) "Produce" means any substance produced for human consumption and nourishment using horticultural techniques, such as vegetables, fruits, grains, mushrooms, honey, herbs, nuts, seeds, and rootstock.
  (3A) "Substantially free of contamination" means that the levels of arsenic, lead, and heavy metals in the soil fall within the acceptable parts per million range identified in regulations promulgated by the Mayor.
  (4) "Urban farm" means any property in the District of Columbia that is used for the growing, cultivating, processing, and distributing of crops for profit, not for profit, or for educational purposes. The term "urban farm" shall not include backyard or community gardens.
  (5) "Vacant land" means land located in the District of Columbia that:
    (A) Consists of at least 2,500 contiguous square feet of unimproved land; and
    (B) Is not the subject of a pending agreement for development or sale.
D.C. Code § 48-831.23 — DC Code / Title 48 / Chapter 8A / § 48-831.23
§ 48-831.23. Payment for drugs by low-income elderly.
Status: in_force

(a) The Director shall establish the amount of payment to be made by eligible low-income elderly individuals toward the cost of prescription or nonprescription drugs, medications, and medical supplies furnished under AccessRx for low-income elderly; provided, that:
  (1) The total cost paid by the low-income elderly individual for any covered purchase of a prescription or nonprescription drug or medication provided under the basic component of AccessRx does not exceed 20% of the price allowed for that prescription under AccessRx rules, or $2, whichever is greater; and
  (2) For the supplemental component of AccessRx, except as otherwise provided in this section, the total cost paid by the low-income elderly individual for any covered purchase of a prescription drug or medication shall not exceed 50% of the price allowed for that prescription under AccessRx.
(b) Prior to January 1, 2006, the Director shall establish annual limits on the costs incurred by eligible household members for prescription or nonprescription drugs or medications covered under AccessRx for low-income elderly. After the annual limits have been established, beginning on January 1, 2007, AccessRx for low-income elderly shall pay 80% of the cost of all prescription or nonprescription drugs or medications covered by the supplemental component of AccessRx. The limits shall be set by the Director by regulation as necessary to operate the program within the AccessRx for low-income elderly budget.
D.C. Code § 48-632 — DC Code / Title 48 / Chapter 6 / § 48-632
§ 48-632. Uniform application of examinations, inspection, and rules and regulations.
Status: repealed

Repealed.
D.C. Code § 48-311 — DC Code / Title 48 / Chapter 3A / § 48-311
§ 48-311. Definitions.
Status: in_force

For the purposes of this chapter , the term:
(1) "Food access" means the ability of an individual or a family to consistently obtain affordable, nutritious food equitably across geography and income level.
(2) "Food assets" means any resource or capacity, whether physical or skill-based, in the growth, production, processing, distribution, disposal, or repurposing of food.
(3) Repealed.
(4) "Food procurement" means the purchasing of or contracting for large volumes of locally grown food either directly from farms or from vendors by large entities either public or private, including schools, hospitals, and prisons.
(5) "Local food economy" means an individual, organization, or business that maintains a presence in the District and is involved in the growth, production, processing, distribution, disposal, or repurposing of food within the District.
(6) "Locally grown" means from a grower in Delaware, the District, Maryland, New Jersey, North Carolina, Pennsylvania, Virginia, or West Virginia.
(6A) "Low food access area" shall have the same definition as in § 7-742.21(7) .
(7) "Urban agriculture" means the practice of growing, cultivating, processing, and distributing vegetables, fruits, grains, mushrooms, honey, herbs, nuts, seeds, and rootstock within the District.
D.C. Code § 48-502 — DC Code / Title 48 / Chapter 5 / § 48-502
§ 48-502. Sale of horse meat and horse meat product—Violations.
Status: repealed

Repealed.
D.C. Code § 48-1203 — DC Code / Title 48 / Chapter 12 / § 48-1203
§ 48-1203. Penalties.
Status: in_force

(a) A person 18 years of age or older who commits a civil violation of § 48-1201 shall be subject to a civil fine of $25 and seizure of any marijuana and paraphernalia visible to the police officer at the time of the civil violation.
(b) (1) A person under the age of 18 years who commits a civil violation of § 48-1201 shall be subject to a civil fine of $25 and seizure of any marijuana and paraphernalia visible to the police officer at the time of the civil violation.
  (2) The Office of Administrative Hearings shall mail a copy of the notice of violation to the parent or guardian of the person to whom the notice of violation is issued at the address provided by the person at the time the citation is issued pursuant to § 48-1202 .
  (3) For the purposes of this subsection, the term “civil violation” shall have the same meaning as a civil Notice of Violation for the purposes of § 16-2333(a)(1A) .
(c) Except as provided in this section, the District shall not request or impose any other form of penalty, sanction, forfeiture, or disqualification for violations of § 48-1201 ; provided, that this subsection does not apply to District government employers if drug use is specifically prohibited as a condition of employment, nor shall this subsection apply to Unit A of Chapter 25 of Title 7 [ § 7-2501.01 et seq.] and Chapter 45 of Title 22 [ § 22-4501 et seq.].
D.C. Code § 48-501 — DC Code / Title 48 / Chapter 5 / § 48-501
§ 48-501. Sale of horse meat and horse meat product — labeling.
Status: repealed

Repealed.
D.C. Code § 48-1003 — DC Code / Title 48 / Chapter 10 / § 48-1003
§ 48-1003. Notice of a drug free zone.
Status: in_force

(a) Upon the designation of a drug free zone, the Police Department shall mark each block within the drug free zone by using barriers, tape, or police officers that post the following information in the immediate area of, and borders around, the drug free zone:
  (1) A statement that it is unlawful for a person to congregate in a group of 2 or more persons for the purpose of committing an offense under subchapter IV of Chapter 9 of this title within the boundaries of a drug free zone, and to fail to disperse after being instructed to disperse by a uniformed officer of the Police Department who reasonably believes the person is congregating for the purpose of committing an offense under subchapter IV of Chapter 9 of this title ;
  (2) The boundaries of the drug free zone;
  (3) A statement of the effective dates of the drug free zone designation; and
  (4) Any other additional notice to inform the public of the drug free zone.
D.C. Code § 48-803.06 — DC Code / Title 48 / Chapter 8 / § 48-803.06
§ 48-803.06. Pharmacist notification to prescriber of substitution of interchangeable biological product.
Status: in_force

(a) Within 5 business days after dispensing a biological product to a patient, the dispensing pharmacist or the pharmacist's designee shall communicate to the prescriber the specific biological product dispensed, including the name and manufacturer of the biological product; except, that this communication shall not be required if the FDA has not approved an interchangeable biological product for the biological product prescribed to the patient or a refill prescription is not changed from the biological product dispensed on the most recent filling of the prescription.
(b) (1) Except as provided under subsection (c) of this section, the communication required under subsection (a) of this section shall be provided by making an entry that is electronically accessible to the health care provider through:
    (A) An interoperable electronic medical records system;
    (B) An electronic prescribing technology; or
    (C) A pharmacy benefits management system.
  (2) Making an entry through a mechanism listed in paragraph (1) of this subsection shall be presumed to provide the communication to the prescriber required under subsection (a) of this section.
(c) If the mechanisms listed in subsection (b)(1) of this section are unavailable, the communication required under subsection (a) of this section may be provided by facsimile, telephone, electronic transmission, or other means.
(d) The requirements under subsections (a) through (c) of this section shall not apply to dispensing pharmacists or their designees at a health maintenance organization that operates as a group model for services furnished through internal pharmacy operations for members and patients of the health maintenance organization.
D.C. Code § 48-715 — DC Code / Title 48 / Chapter 7 / § 48-715
§ 48-715. Exceptions.
Status: in_force

This chapter shall not apply to any cosmetic unless the cosmetic is a drug as defined by § 201 of the Food, Drug and Cosmetic Act [21 U.S.C. § 321  ].
D.C. Code § 48-110 — DC Code / Title 48 / Chapter 1 / § 48-110
§ 48-110. Inconsistent acts repealed; certain Acts preserved.
Status: in_force

(a) The Mayor shall issue rules in accordance with subchapter I of Chapter 5 of Title 2 , to implement the provisions of this chapter. The proposed rules shall be submitted to the Council for a 45-day period of review, excluding Saturdays, Sundays, legal holidays, and days of Council recess. If the Council does not approve or disapprove the proposed regulations, in whole or part, by resolution, within this 45-day review period, the proposed regulations shall be deemed disapproved.
(b) The Mayor shall establish, by rule, a license application fee for a food establishment. The fee shall be set in an amount to recoup some or all of the costs to the District of Columbia for reviewing the application. The regulations may also provide for interest to be charged on late payments of any charges imposed pursuant to this chapter.
D.C. Code § 48-706 — DC Code / Title 48 / Chapter 7 / § 48-706
§ 48-706. Conditional license.
Status: in_force

The Mayor may issue a conditional license to a person if the person does not meet all of the requirements of this chapter, the rules issued pursuant to this chapter, or any applicable federal law, provided the failure to meet the requirements does not endanger the health, safety, or welfare of the community, and the Mayor mandates that the requirements be met by a specific date.
D.C. Code § 48-904.04 — DC Code / Title 48 / Chapter 9 / § 48-904.04
§ 48-904.04. Penalties under other laws.
Status: in_force

Any penalty imposed for violation of this chapter is in addition to, and not in lieu of, any civil or administrative penalty or sanction otherwise authorized by law.
D.C. Code § 48-851.02 — DC Code / Title 48 / Chapter 8F / § 48-851.02
§ 48-851.02. Safe disposal of unused pharmaceuticals.
Status: in_force

(a) (1) The Board of Pharmacy shall design a public education campaign to educate individuals on:
    (A) The importance of promptly disposing of unused pharmaceuticals to avoid accidental overdoses, medication errors, and household drug theft;
    (B) How disposing of pharmaceuticals by flushing them into the public sewer system or throwing them in the trash can be harmful to the environment and can contaminate the drinking water supply; and
    (C) How to dispose of unused pharmaceuticals in a safe and environmentally sound manner.
  (2) Each retail pharmacy licensed in the District of Columbia shall implement the public education campaign as required by the Board of Pharmacy.
(b) (1) By July 1, 2010, the Board of Pharmacy shall make recommendations to the Mayor regarding the establishment of a program to enable consumers to dispose of unused pharmaceuticals, including controlled substances, in a safe and environmentally sound manner.
  (2) In developing recommendations, the Board of Pharmacy shall give consideration to a mail-in program that:
    (A) Utilizes prepaid mailing envelopes that allow an individual to mail unused pharmaceuticals to a single collection location approved for all pharmaceuticals including controlled substances;
    (B) Distributes the prepaid mailing envelopes to the public at various locations, including to all retail pharmacies;
    (C) Provides for the collected pharmaceuticals to be disposed of in a manner that is:
      (i) Safe;
      (ii) Secure;
      (iii) Environmentally sound; and
      (iv) In compliance with District and federal environmental requirements; and
    (D) Randomly assesses the toxicity of pharmaceuticals received; provided, that the assessment results do not identify the:
      (i) Patient;
      (ii) Person who mailed the material;
      (iii) Prescriber; or
      (iv) Pharmacy.
D.C. Code § 48-832.03 — DC Code / Title 48 / Chapter 8A / § 48-832.03
§ 48-832.03. Enforcement.
Status: in_force

A violation of this subchapter is a violation of Chapter 39 of Title 28 , for which a fine of not more than $10,000 may be adjudged.
D.C. Code § 48-855.02 — DC Code / Title 48 / Chapter 8H / § 48-855.02
§ 48-855.02. Specialty drug copayment or coinsurance limitation.
Status: in_force

(a) (1) A health benefit plan that provides coverage for prescription drugs shall ensure that a required copayment or coinsurance applicable to a drug on a specialty tier does not exceed $150 per month for up to a 30-day supply of the specialty drug or $300 for a 90-day supply.
  (2) On July 1 of each year, the limit on a required copayment or coinsurance applicable to a drug on a specialty tier provided in paragraph (1) of this subsection shall increase by a percentage equal to the percentage change from the preceding year in the medical care component of the March Consumer Price Index for All Urban Consumers, Washington-Arlington-Alexandria, DC-VA-MD-WV metropolitan area, as published by the Bureau of Labor Statistics of the United States Department of Labor.
(b) (1) For a health benefit plan that provides coverage for prescription drugs and utilizes a tiered formulary, a member or member representative shall have the right to request that a non-preferred drug be covered under the cost sharing applicable for preferred drugs if the prescribing physician determines that the preferred drug for treatment of the same condition either would not be as effective for the individual or would have adverse effects for the individual, or both.
  (2) The denial of a request made pursuant to paragraph (1) of this subsection shall be considered an adverse event and shall be subject to the health benefit plan's internal review process.
(c) A health benefit plan that provides coverage for prescription drugs shall not place all drugs in a given class of drugs on a specialty tier.
(d) Nothing in this section shall be construed to require a health benefit plan to:
  (1) Provide coverage for any additional drugs not otherwise required by law;
  (2) Implement specific utilization management techniques, such as prior authorization or step therapy; or
  (3) Cease the use of tiered cost-sharing structures, including strategies used to incentivize use of preventive services, disease management, and low-cost treatment options.
(e) Nothing in this section shall be construed to require a pharmacist to substitute a drug without the consent of the prescribing physician.
(f) A health insurer shall not be precluded from requiring specialty drugs to be obtained through a designated pharmacy or other source of specialty drugs.
D.C. Code § 48-804.01 — DC Code / Title 48 / Chapter 8 / § 48-804.01
§ 48-804.01. Violations of posting provisions.
Status: in_force

(a) Any pharmacy which sells a legend drug in violation of § 48-801.03 , § 48-801.04 , or § 48-801.05 is liable to the buyer, or the provider or insurer of the buyer, for the full amount charged for the drug.
(b) Civil fines, penalties, and fees may be imposed as alternative sanctions for any infraction of the provisions of this subchapter, or any rules or regulations issued under the authority of this subchapter, pursuant to Chapter 18 of Title 2 . Adjudication of any infraction of this subchapter shall be pursuant to Chapter 18 of Title 2 .
D.C. Code § 48-931.02 — DC Code / Title 48 / Chapter 9B / § 48-931.02
§ 48-931.02. Supervision by licensed practitioner.
Status: in_force

A licensed practitioner, in good faith and in the course of professional practice only, may cause controlled substances to be administered by a nurse, certified emergency medical technician/paramedic, certified emergency medical technician/intermediate paramedic, or intern under the licensed practitioner’s direction and supervision.
D.C. Code § 48-903.08 — DC Code / Title 48 / Chapter 9 / § 48-903.08
§ 48-903.08. Prescriptions.
Status: in_force

(a) Except when dispensed directly by a practitioner, other than a pharmacy, to an ultimate user, no controlled substance in Schedule II may be dispensed without the written prescription of a practitioner.
(b) In emergency situations, as defined by rule of the Mayor, Schedule II drugs may be dispensed upon oral prescription of a practitioner, reduced promptly to writing and filed by the pharmacy. Prescriptions shall be retained in conformity with the requirements of § 48-903.06 . No prescription for a Schedule II controlled substance may be refilled.
(c) Except when dispensed directly by a practitioner, other than a pharmacy, to an ultimate user, a controlled substance included in Schedule III or IV which is a prescription drug as determined under § 353(b) of Title 21, United States Code, shall not be dispensed without a written or oral prescription of a practitioner. The prescription shall not be filled or refilled more than 6 months after the date thereof or be refilled more than 5 times, unless renewed by the practitioner.
(d) A controlled substance included in Schedule V shall not be distributed or dispensed other than for a medical purpose.
(e) Whenever a practitioner dispenses any controlled substance on a written or oral prescription issued by a practitioner, the practitioner shall affix to the container in which such controlled substance is dispensed a label showing the name of the controlled substance or controlled substances contained therein unless otherwise so indicated by the prescribing practitioner; the serial number and date of initial filling; the directions for use; the practitioner’s name and registry number; the name of the ultimate user, or if the ultimate user is an animal, the name of the owner and the species of the animal; the name of the practitioner issuing the prescription; and caution statements, if any, as required by law.